Structured molecular vectors for anti-inflammatory compounds and uses thereof - Patents.com
New ethanolamine-based molecular vectors address inefficiencies in existing omega-3 fatty acid delivery by enhancing brain targeting and sustainability, offering effective anti-inflammatory and cognitive restoration benefits.
Patent Information
- Application Number
- JP2021549472
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-10-23
- Filing Date
- 2020-02-21
- Publication Date
- 2024-11-07
- Estimated Expiration
- 2040-02-21
AI Technical Summary
Current omega-3 fatty acid vectors, such as ethyl and triglyceride forms, suffer from inefficiencies in biodisponibility and brain targeting, while glycerophospholipid forms derived from whole krill extracts are molecularly impure and environmentally unsustainable, lacking effective long-term delivery and brain accumulation.
Development of new molecular vectors, including ethanolamine, ethanolamine-phosphonate, and ethanolamine-phosphate derivatives of saturated or unsaturated fatty acids, specifically sphingosynaptolipoxins (SSLs) and aminoglycerophosphosynaptolipoxins (AGPSLs), which exhibit strong anti-inflammatory activity and improve cognitive function and reduce seizure severity.
These new vectors provide acute and long-lasting delivery of biologically active compounds, effectively reducing inflammation and seizure frequency, restoring cognitive function, and targeting neurological disorders with inflammatory components.
Smart Images

Figure 0007579266000017 
Figure 0007579266000018 
Figure 0007579266000019
Abstract
Description
[Technical field]
[0001] The present invention relates to vector compounds of various biologically active compounds, which have particularly strong anti-inflammatory properties, allowing cognitive recovery and prevention of cognitive decline, and / or reducing the severity and frequency of attacks.The present invention also relates to the use of such compounds in the treatment of neurological, psychiatric and peripheral disorders, and in particular disorders of inflammatory origin.The present invention also relates to ethanolamine, ethanolamine-phosphonate and ethanolamine-phosphate fatty acid derivatives, and their use in the same therapeutic and non-therapeutic applications. [Background technology]
[0002] Considering their numerous advantages, omega-3 fatty acid type compounds represent an important market in the health domain.Indeed, these compounds are active in the prevention of many diseases that have inflammation as a common denominator.Inflammation is a component of many diseases or disorders, such as arthritic, cardiovascular and neurological disorders.
[0003] Currently, omega-3 compounds found on the market are limited to two families of fatty acid vectors: ethyl form and triglyceride form.In terms of pharmacology, the ethyl form is relatively inefficient, partly due to its poor bioavailability and its poor brain targeting.The triglyceride form is the latest vectored form on the market today, and also shows conflicting results in terms of efficacy and brain targeting.
[0004] Therefore, a new kind of omega-3 fatty acid vector has appeared on the market.These glycerophospholipid-type vectors have the advantage of better brain accumulation when compared with ethyl- and triglyceride-type vectors.However, these glycerophospholipid-type vectors are generally obtained from whole extracts, such as whole krill extracts, which are impure at the molecular level.In addition, the use of these glycerophospholipid-type vectors obtained from krill extracts contributes to the shortage of aquatic resources, thus raising environmental and sustainable development issues.
[0005] The glycerophospholipid vectors of omega-3 fatty acids that have been developed are, for example, phosphatidylserine vectors.Furthermore, lysophosphatidylcholine mimic vectors for certain families of omega-3 fatty acids, including docosahexaenoic acid or DHA (WO2018 / 162617).Although glycerophospholipid-based vectors have better brain targeting than ethyl and triglyceride form-based vectors, they have the disadvantage of being monovalent vectors of fatty acids (e.g., docosahexanoic acid only) that only use short-term delivery. [Prior art documents] [Patent documents]
[0006] [Patent Document 1] WO2018 / 162617 [Patent Document 2] WO2004.092414 [Non-patent literature]
[0007] [Non-Patent Document 1] J. Pharm. Sci. 1977, 66, 2 [Non-Patent Document 2] Handbook of Pharmaceutical Salts: Properties, Selection, and Use, edited by P. Heinrich Stahl and Camille G. Wermuth, 2002 [Non-Patent Document 3] Folch J., Lees M. and Stanley GHS; (1957); A simple method for the isolation and purification of total lipids from animal tissues. J. Biol. Chem. 226, 497~509 [Non-Patent Document 4] Digestion of Phospholipids after Secretion of Bile into the Duodenum Changes the Phase Behavior of Bile Components. Woldeamanuel A. Birru. et al., Mol. Pharmaceutics, 2014, 11, 2825~2834 [Non-Patent Document 5] Loscher et al., 2011, Seizure 20, 359–368 Summary of the Invention [Problem to be solved by the invention]
[0008] Therefore, there is currently a strong need to develop new vector compounds that allow the delivery of one or more active compounds, such as fatty acids, in an acute (short-term) and long-lasting (long-term) manner along the gastrointestinal tract, in order to provide effective treatment not only in cases of inflammation and epileptic seizures, but also in the preservation and / or restoration of cognitive function, whether or not associated with behavioral and / or psychoaffective disorders.The development of fatty acid derivatives also remains an important need in these applications. [Means for solving the problem]
[0009] The inventors have developed a new family of molecular vectors and new active compounds, in particular ethanolamine, ethanolamine-phosphonate or ethanolamine-phosphate derivatives of saturated or unsaturated fatty acids. The active compounds have strong anti-inflammatory activity and can reduce attack severity and frequency and / or restore or improve cognitive functions that may be altered in neurological disorders with a significant inflammatory component. The new family of molecular vectors includes two subfamilies: sphingosynaptolipoxins (SSL) and aminoglycerophosphosynaptolipoxins (AGPSL).
[0010] Thus, the present invention provides a compound of formula (I):
[0011] [ka]
[0012] [In the formula, n is an integer equal to 0 or 1, ○ A is A group of formula (A'):
[0013] [ka]
[0014] {In the formula, - R 1' is a saturated or unsaturated (C1-C6) alkyl group optionally substituted with at least one group selected from hydroxyl and halogen; 24 ) an alkyl chain, - R 2' represents hydrogen, a saturated or unsaturated fatty acyl containing from 2 to 30 carbon atoms, one of its oxygen derivatives, or a biologically active compound attached to the remainder of the molecule by an acyl group; or A group of formula (A"):
[0015] [ka]
[0016] {In the formula, - R 1" represents a preferably saturated fatty acyl containing from 2 to 30 carbon atoms, - R 2" represents hydrogen, a saturated or unsaturated fatty acyl containing from 2 to 30 carbon atoms, one of its oxygen derivatives, or a biologically active compound attached to the remainder of the molecule by an acyl group. represents a group selected from R3 represents hydrogen, a saturated or unsaturated fatty acyl containing from 2 to 30 carbon atoms, one of its oxygen derivatives, or a biologically active compound bound to the remainder of the molecule by an acyl group; R4 represents hydrogen or a (C1-C6) alkyl group. and its hydrates, or diastereoisomers, or pharmacologically acceptable salts.
[0017] In certain embodiments, the compound of the present invention has formula (I'):
[0018] [ka]
[0019] [In the formula, n is an integer equal to 0 or 1, ○ R 1' is a saturated or unsaturated (C1-C6) alkyl group optionally substituted with at least one group selected from hydroxyl and halogen; 24 ) an alkyl chain, ○ R 2' represents hydrogen, a saturated or unsaturated fatty acyl containing from 2 to 30 carbon atoms, one of its oxygen derivatives, or a biologically active compound bound to the remainder of the molecule by an acyl group; R3 represents hydrogen, a saturated or unsaturated fatty acyl containing from 2 to 30 carbon atoms, one of its oxygen derivatives, or a biologically active compound bound to the remainder of the molecule by an acyl group; R4 represents hydrogen or a (C1-C6) alkyl group, preferably a methyl group. has.
[0020] In a further particular embodiment, the compound of the present invention has formula (I"):
[0021] [ka]
[0022] [In the formula, n is an integer equal to 0 or 1, ○ R 1" represents a preferably saturated fatty acyl containing from 2 to 30 carbon atoms, ○ R 2" represents hydrogen, a saturated or unsaturated fatty acyl containing from 2 to 30 carbon atoms, one of its oxygen derivatives, or a biologically active compound bound to the remainder of the molecule by an acyl group; R3 represents hydrogen, a saturated or unsaturated fatty acyl containing from 2 to 30 carbon atoms, one of its oxygen derivatives, or a biologically active compound bound to the remainder of the molecule by an acyl group; R4 represents hydrogen or a (C1-C6) alkyl group, preferably a methyl group. has.
[0023] In a preferred embodiment, R3 in formulae (I), (I') and (I") is not hydrogen.
[0024] In a preferred embodiment, R 2' , R 2" and R3 is ○ R 2' and R 2" But independently, - Hydrogen, - saturated or unsaturated fatty acyls containing from 2 to 30 carbon atoms, selected from the group consisting of acetic acid, propionic acid, butyric acid, valeric acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, lignoceric acid, myristoleic acid, palmitoleic acid, oleic acid, vaccenic acid, linoleic acid, alpha-linoleic acid, arachidonic acid, eicosapentaenoic acid, erucic acid and docosahexaenoic acid, preferably docosahexaenoic acid, or - represents an oxygen derivative of a saturated or unsaturated fatty acyls having from 2 to 30 carbon atoms, selected from resolvins, maresins, neuroprotectins and neuroprostanes, ○ R3 is - saturated or unsaturated fatty acyls containing from 2 to 30 carbon atoms, selected from the group consisting of acetic acid, propionic acid, butyric acid, valeric acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, lignoceric acid, myristoleic acid, palmitoleic acid, oleic acid, vaccenic acid, linoleic acid, alpha-linoleic acid, arachidonic acid, eicosapentaenoic acid, erucic acid and docosahexaenoic acid, preferably docosahexaenoic acid, or - oxygen derivatives of saturated or unsaturated fatty acyls containing from 2 to 30 carbon atoms selected from resolvins, maresins, neuroprotectins and neuroprostanes; It is as if it represents:
[0025] The present invention further relates to an ethanolamine, ethanolamine-phosphonate or ethanolamine-phosphate derivative of a saturated or unsaturated fatty acid containing from 2 to 30 carbon atoms, or one of its oxygen derivatives, which can be delivered by a vector as disclosed herein.
[0026] Thus, the present invention relates to a compound of formula (II): R5-NH-CH2-CH(R7)-O (n) -R6(II) [In the formula, n is an integer equal to 0 or 1, R5 represents a saturated or unsaturated fatty acyl containing from 2 to 30 carbon atoms or one of its oxygen derivatives, ○ R6 is -PO3 2- It is based on R7 represents hydrogen or a (C1-C6) alkyl group; With the proviso that when n is equal to 1, R5 is not arachidonic acid; and It also relates to the hydrates, or diastereoisomers, or pharmacologically acceptable salts thereof.
[0027] In a preferred embodiment, the compound of formula (II) is ○ n is an integer equal to 0, R5 represents a saturated or unsaturated fatty acyl group containing from 2 to 30 carbon atoms, which is docosahexaenoic acid; ○ R7 represents hydrogen It's like that.
[0028] In a further preferred embodiment, R5 is saturated or unsaturated fatty acyls containing from 2 to 30 carbon atoms, selected from the group consisting of acetic acid, propionic acid, butyric acid, valeric acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, lignoceric acid, myristoleic acid, palmitoleic acid, oleic acid, vaccenic acid, linoleic acid, alpha-linoleic acid, arachidonic acid, eicosapentaenoic acid, erucic acid and docosahexaenoic acid, preferably capric acid, eicosapentaenoic acid and docosahexaenoic acid, or - oxygen derivatives of saturated or unsaturated fatty acyls containing from 2 to 30 carbon atoms selected from resolvins, maresins, neuroprotectins and neuroprostanes; Represents.
[0029] A further object of the present invention is a compound of formula (I), (I'), (I") or (II) for use as a medicine.
[0030] A further object of the present invention is the use of a compound of formula (I), (I'), (I") or (II) as a dietary supplement.
[0031] The present invention further relates to pharmaceutical compositions comprising at least one compound of formula (I), (I'), (I") or (II) and an acceptable pharmaceutical excipient.
[0032] A particular embodiment of the present invention is a pharmaceutical composition as disclosed herein for use in preventing and / or treating a disease selected among an inflammatory disease or a disease associated with cognitive impairment. Preferably, the inflammatory disease is an inflammatory disease of the central nervous system, an inflammatory disease of the gastrointestinal tract, an inflammatory joint disease or an inflammatory disease of the retina.
[0033] A further particular embodiment of the present invention is a pharmaceutical composition as disclosed herein for use in preventing and / or treating a disease selected from the group consisting of epilepsy, traumatic brain injury, Alzheimer's disease, Parkinson's disease, multiple sclerosis, Crohn's disease, bowel syndrome, dementia and Huntington's disease.
[0034] A further particular embodiment of the present invention is a pharmaceutical composition as disclosed herein for use to prevent cognitive decline or to restore cognitive function altered in brain injury or damage and / or in traumatic brain injury and / or in neuroinflammatory diseases and / or in neurodegenerative diseases.
[0035] Another object of the present invention is to provide a compound of formula (II'): R 5' -NH-CH2-CH(R 7' )-O (n) -R 6' (II') [In the formula, ○ n is an integer equal to 1, ○ R 5' represents a saturated or unsaturated fatty acyl containing from 2 to 30 carbon atoms or one of its oxygen derivatives, ○ R 6' is hydrogen, ○ R 7' represents hydrogen or a (C1-C6) alkyl group, and and a hydrate, or a diastereoisomer, or a pharmacologically acceptable salt thereof, A pharmaceutical composition for use in preventing and / or treating a cognition-related disease or a disease selected from the group consisting of epilepsy, traumatic brain injury, Alzheimer's disease, Parkinson's disease, multiple sclerosis, Crohn's disease, bowel syndrome, dementia and Huntington's disease.
[0036] Another object of the present invention is a pharmaceutical composition comprising an acceptable pharmaceutical excipient and a compound of formula (II') as defined above for use in preventing cognitive decline or in restoring cognitive functions altered in brain injury and / or in traumatic brain injury and / or in neuroinflammatory diseases and / or in neurodegenerative diseases.
[0037] In a preferred embodiment, R 5' teeth, saturated or unsaturated fatty acyls containing from 2 to 30 carbon atoms, selected from the group consisting of acetic acid, propionic acid, butyric acid, valeric acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, lignoceric acid, myristoleic acid, palmitoleic acid, oleic acid, vaccenic acid, linoleic acid, alpha-linoleic acid, arachidonic acid, eicosapentaenoic acid, erucic acid and docosahexaenoic acid, preferably capric acid, eicosapentaenoic acid and docosahexaenoic acid, or - oxygen derivatives of saturated or unsaturated fatty acyls containing from 2 to 30 carbon atoms selected from resolvins, maresins, neuroprotectins and neuroprostanes; Represents.
[0038] According to a preferred embodiment, the pharmaceutical compositions as disclosed herein are administered by the oral route. [Brief description of the drawings]
[0039] [Figure 1] FIG. 1 shows a general procedure for the preparation of SSL-X compounds. [Diagram 2] FIG. 1 shows separation of SSL-X1, SSL-X2 and SSL-X3 on an aminopropyl (LC-NH2) column. [Diagram 3] Figure 3: Hydrolysis of SSL-X1 in the digestive tract. Each animal was given 227 μg of SSL-X1 orally and feces were collected after 16, 21, 26, 40 and 50 hours. A: Amount of SSL-X1 measured in feces at various time points. B: Amount of administered molecule (Adm), total amount measured in feces at various time points (feces) and amount hydrolyzed / adsorbed (Hydrolysis / Adsorption). These amounts, expressed in μg of phosphorus (P) in SSL-X1, were calculated assuming that the amount of SSL-X1 (Hydrolysis / Adsorption) corresponds to the amount administered minus the amount measured accumulated in the feces in total. Results are the mean ± standard deviation of 5 independent experiments. [Figure 4] Figure 1 shows the time-dependent distribution of SSL-X1 along the intestinal tract of treated rats. Each animal was given 227 μg of SSL-X1 orally. Rats were sacrificed 5 hours (panel A), 8 hours (panel B) and 36 hours (panel C) after administration of the molecule. The intestinal tract was removed and cut approximately every 10 cm. The contents of each section were collected and lipids were extracted and purified as described. The amount of SSL-X1 in each lipid extract was determined by phosphorus determination. [Diagram 5] FIG. 1 shows a protocol for testing the effect of synaptamide phosphonates on the expression of inflammatory markers in human microglia activated by IL-1β. [Figure 6] FIG. 1 shows that synaptamide phosphonate (SYN Pn) reduces IL-1β-mediated induction of proinflammatory markers in immortalized human microglial cells. IHM microglial cells were treated with various concentrations of SYN Pn as indicated 3 hours prior to exposure to IL-1β. RNA from inflammatory markers was extracted 5 hours after IL-1β treatment and quantified by RT-qPCR. Results are expressed as % of (IL-1β-NaCl) ± SEM (n=3). [Figure 7] Figure 1 shows the in vivo effect of synaptamide and synaptamide phosphonate on LPS-induced neuroinflammation in rats. LPS was injected into 21-day-old pups. One minute after LPS injection, animals received synaptamide (SYN) or synaptamide phosphonate (SYN Pn) at a dose of 2 mg / Kg synaptamide equivalent. Rats were sacrificed 6 hours after injection of LPS and hippocampus and neocortex were collected. Expression levels of inflammation marker transcripts were determined by RT-qPCR. IL1β: Interleukin 1 beta; IL6: Interleukin 6; TNFα: TNF alpha. Neuroinflammation index (IN) was determined from data acquired in hippocampus and neocortex. CTR: control rats. Results are expressed as mean ± SEM (n=5). [Figure 8] Figure 1 shows the effect of SSL-X1 vector on SE-induced neuroinflammation in rats. 21-day-old rats were subjected to SE. SSL-X1 vector was administered orally 1 h after the onset of SE. Brain structures of interest (hippocampus and ventral limbic area) were harvested 24 h after SE. Interleukin 6 (IL6), cyclooxygenase 2 (COX2) and chemokine MCP1 (MCP1) mRNA levels were determined by RT-qPCR. CTRL: control administered with NaCl; SE-NaCl: group of rats subjected to SE and administered with NaCl; SE-SSL-X1: group of rats subjected to SE and administered with vector SSL-X1; HI: hippocampus; VLR: ventral limbic area. Results are expressed as mean ± SEM (n=7-10). [Figure 9A] Hippocampal LTP is attenuated 1 to 2 weeks after Pilo-SE and rescued by synaptamide. Summary time course of excitatory postsynaptic potential (EPSP) amplitude before and after induction of long-term potentiation (LTP) by theta burst paired protocol stimulation (TBP, indicated by arrow) in hippocampal slices from healthy rats (Cont) and animals subjected to Pilo-SE (SE) (left). [Figure 9B]Hippocampal LTP is attenuated 1 to 2 weeks after Pilo-SE and rescued by synaptamide.LTP induction in hippocampal slices from rats subjected to Pilo-SE and perfused with either 100 nM synaptamide-free artificial cerebrospinal fluid (ACSF) (SE) or synaptamide (SE-SYN) (left). [Figure 9C] Hippocampal LTP is attenuated 1 to 2 weeks after Pilo-SE and rescued by synaptamide.LTP induction in hippocampal slices from rats subjected to Pilo-SE and perfused with either 400 nM synaptamide-free artificial cerebrospinal fluid (ACSF) (SE) or synaptamide (SE-SYN) (left). [Figure 9D] Hippocampal LTP is attenuated 1 to 2 weeks after Pilo-SE and rescued by synaptamide.LTP induction in hippocampal slices from rats subjected to Pilo-SE and injected with either NaCl (SE) or synaptamide (SE-SYN, 2 mg / kg; i.p.) (left). [Figure 9E] Figure 1: Hippocampal LTP is attenuated 1 to 2 weeks after Pilo-SE and rescued by synaptamide. LTP induction in hippocampal slices from rats subjected to Pilo-SE and injected (i.p.) with either 2 or 10 mg / kg NaCl (SE) or synaptamide (SE-SYN) (left). Synaptamide was administered 1 h after the cessation of SE and then daily for 6 days. The control group received saline solution only. In all subsequent figures, summary data are presented as mean ± SEM, numbers in brackets indicate the number of cells, and histograms (right) show the mean amplitude (± SEM) of EPSPs measured during the last 5 min of recording in each condition. *p<0.05, **p<0.01, ***p<0.001. [Figure 10A] Figure 1: Hippocampal LTP is rescued by synaptamide phosphate 1 to 2 weeks after Pilo-SE.LTP induction in hippocampal slices from rats subjected to Pilo-SE and perfused with either 100 nM synaptamide phosphate-free ACSF (SE) or synaptamide phosphate (SE-SYN Ph). [Figure 10B] Figure 1: Hippocampal LTP is rescued by synaptamide phosphate 1 to 2 weeks after Pilo-SE.LTP induction in hippocampal slices from rats subjected to Pilo-SE and perfused with either 400 nM synaptamide phosphate-free ACSF (SE) or synaptamide phosphate (SE-SYN Ph). [Figure 10C] Figure 1: Hippocampal LTP is rescued by synaptamide phosphate 1 to 2 weeks after Pilo-SE.LTP induction in hippocampal slices from rats subjected to Pilo-SE and injected with either NaCl (SE) or synaptamide phosphate (SE-SYN Ph, 5 mg / kg; i.p.). [Figure 10D] Figure 1: Hippocampal LTP is rescued by synaptamide phosphate 1 to 2 weeks after Pilo-SE. LTP induction in hippocampal slices from rats subjected to Pilo-SE and injected (ip) with either 2 mg / kg NaCl (SE) or synaptamide phosphate (SE-SYNPh) (left). Synaptamide phosphate was administered 1 hour after the cessation of SE and then daily for 6 days. Control groups received saline solution only. *p<0.05, **p<0.01, ***p<0.001. [Figure 11A] Figure 1: Hippocampal LTP is rescued by synaptamide phosphonate 1 to 2 weeks after Pilo-SE.LTP induction in hippocampal slices from rats subjected to Pilo-SE and perfused with either 100 nM synaptamide phosphonate-free ACSF (SE) or synaptamide phosphonate (SE-SYN Pn). [Figure 11B] Figure 1: Hippocampal LTP is rescued by synaptamide phosphonate 1 to 2 weeks after Pilo-SE.LTP induction in hippocampal slices from rats subjected to Pilo-SE and perfused with either 400 nM synaptamide phosphonate-free ACSF (SE) or synaptamide phosphonate (SE-SYN Pn). [Figure 11C]Figure 1: Hippocampal LTP is rescued by synaptamide phosphonate 1 to 2 weeks after Pilo-SE.LTP induction in hippocampal slices from rats subjected to Pilo-SE and injected with either NaCl (SE) or synaptamide phosphonate (SE-SYN Pn, 5 mg / kg; i.p.). [Figure 11D] Hippocampal LTP is rescued by synaptamide phosphonates 1 to 2 weeks after Pilo-SE.LTP induction in hippocampal slices from rats subjected to Pilo-SE and injected (i.p.) with either 2 or 10 mg / kg NaCl (SE) or synaptamide phosphonate (SE-SYN Pn) (left). [Figure 11E] Figure 1: Hippocampal LTP is rescued by synaptamide phosphonate 1 to 2 weeks after Pilo-SE. LTP induction in hippocampal slices from rats subjected to Pilo-SE and treated (orally) with 10, 30 and 100 mg / kg synaptamide phosphonate (SE-SYN Pn). Synaptamide phosphonate was administered 1 hour after the cessation of SE and then daily for 6 days. The control group received saline solution only. *p<0.05, **p<0.01, ***p<0.001. [Figure 12] Figure 12: Synaptamide or synaptamide phosphonate treatment improves hippocampal LTP in healthy rats. Figure 12A: LTP induction in hippocampal slices from healthy rats injected with either NaCl (HT) or synaptamide (HT-SYN, 2 mg / kg; i.p.). Figure 12B: LTP induction in hippocampal slices from healthy rats injected with either NaCl (HT) or synaptamide phosphonate (HT-SYN Pn, 2 mg / kg; i.p.). Synaptamide or synaptamide phosphonate were administered daily for 7 days (P21-P27). The control group received only saline solution. *p<0.05, **p<0.01, ***p<0.001. [Figure 13A] Figure 1 shows the effect of SYN-PN administered intraperitoneally at 5, 10 and 50 mg / kg on seizure severity in fully kindled rats.Total population of rats, n=15. [Figure 13B] Figure 1 shows the effect of SYN-PN administered intraperitoneally at 5, 10 and 50 mg / kg on seizure severity in fully kindled rats, in which a reduction in seizure severity was first observed in response to 5 mg / kg SYN-PN. Results are expressed as mean ± sem. *, p<0.05; **, p<0.01; ***, p<0.001; levels of significance of reduction compared to D0, one-way ANOVA with repeated measures followed by post-hoc Fisher's LSD test. [Figure 13C] Figure 1 shows the effect of SYN-PN administered intraperitoneally at 5, 10 and 50 mg / kg on seizure severity in fully kindled rats, in which a reduction in seizure severity was first observed in response to 10 mg / kg SYN-PN. Results are expressed as mean ± sem. *, p<0.05; **, p<0.01; ***, p<0.001; levels of significance of reduction compared to D0, one-way ANOVA with repeated measures followed by post-hoc Fisher's LSD test. [Figure 13D] Figure 1 shows the effect of SYN-PN administered intraperitoneally at 5, 10 and 50 mg / kg on seizure severity in fully kindled rats, in which a reduction in seizure severity was first observed in response to 50 mg / kg SYN-PN. Results are expressed as mean ± sem. *, p<0.05; **, p<0.01; ***, p<0.001; levels of significance of reduction compared to D0, one-way ANOVA with repeated measures followed by post-hoc Fisher's LSD test. [Figure 14] Figure 1 shows the effect of SYN-PN on seizure severity observed in rats in response to 5, 10 and 50 mg / kg. Results are expressed as mean ± sem. [Figure 15]Figure 15 shows that treatment with synaptamide or synaptamide phosphonate significantly increased the learning ability of epileptic rats. Figure 15A: Graphs showing spatial learning abnormalities in epileptic (Epi, n=14) rats compared to control rats (Cont, n=15), assessed as an increase in the time required to locate the platform during the MWM experiment. Figures 15B-C: Graphs showing improvement in spatial learning in epileptic rats injected with synaptamide (B, Epi-SYN, n=14) or synaptamide phosphonate (C, Epi-SYN-PN, n=14) during the first week after SE, assessed as a decrease in the time required to locate the platform during the MWM experiment. Numbers in brackets indicate the number of rats. Results represent the mean ± SEM. *p<0.05, **p<0.01, ***p<0.001. [Figure 16] FIG. 1 shows that oral administration of 100 mg / kg docosahexaenoic acid does not prevent hippocampal LTP dysfunction after SE. LTP induction in hippocampal slices from rats subjected to Pilo-SE and treated (orally) with either synaptamide phosphonate (SE-SYN Pn; 100 mg / kg) or docosahexaenoic acid (SE-DHA; 100 mg / kg) (left). Synaptamide phosphonate or docosahexaenoic acid was administered 1 hour after the cessation of SE, then daily for 6 days, then once every other day for 2 weeks. *p<0.05, **p<0.01, ***p<0.001. [Figure 17] Oral administration of SSLX2 prevents hippocampal LTP dysfunction after SE. Figures 17A-C: LTP induction in hippocampal slices from rats subjected to Pilo-SE (SE) and treated (orally) with either synaptamide phosphonate (SE-SYN Pn) or SSLX2 (SE-SSLX2) at 10 (A-B) and 30 mg / kg (A and C) (left). Synaptamide phosphonate and SSLX2 were administered 1 h after the cessation of SE, then daily for 6 days, then once every other day for 2 weeks. *p<0.05, **p<0.01, ***p<0.001. [Figure 18]Figure 1 shows that intraperitoneal injection of eicosapentaenoic acid ethanolamine phosphonate and decanoic acid ethanolamine phosphonate prevents hippocampal LTP dysfunction after SE. LTP induction in hippocampal slices from rats subjected to Pilo-SE (SE) and injected (ip) with either decanoic acid ethanolamine phosphonate (SE-DEC-EA-Pn; 5 mg / kg) or eicosapentaenoic acid ethanolamine phosphonate (SE-EPA-EA-Pn; 5 mg / kg) (left). Decanoic acid ethanolamine phosphonate or eicosapentaenoic acid ethanolamine phosphonate was administered 1 h after the cessation of SE, then daily for 6 days, then once every other day for 2 weeks. *p<0.05, **p<0.01, ***p<0.001. [Figure 19] Figure 1 shows the sustained anti-seizure effect of synaptamide phosphonate after treatment was stopped in fully amygdala kindled rats. All fully kindled rats (15) showed seizure severity reduction from 5 mg / kg synaptamide phosphonate (n=8 / 15), 10 mg / kg (n=3 / 15) or 50 mg / kg (n=4 / 15). The solid bars indicate the seizure severity observed after an acute dose of 50 mg / kg in the three subgroups of rats. The hatched bars indicate the seizure severity after four daily doses of 5, 10 or 20 mg / kg synaptamide phosphonate. The dotted bars indicate the long-lasting effect observed on seizure severity after stopping synaptamide phosphonate treatment. Below the x-axis, the number of seizure-free rats for each condition is indicated. Results are expressed as the mean ± SEM of the entire subgroup population (n=8, n=3 or n=4). [Figure 20]Synaptamide phosphonates facilitate recovery of weight loss in rats after SE. On day 0, rats were subjected to pilocarpine-induced status epilepticus and synaptamide phosphonates (SynPn) were administered daily (10 mg / Kg, i.p.) for 7 days. Animals were weighed daily. Results are expressed as percentage of the body weight of animals (10-15 animals / group) on day 0. Statistical differences between control / SE+NaCl (*: p<0.05, ***: p<0.001) and SE+NaCl / SE+SynPn (#: p<0.05). [Figure 21] DECA-EA-Pn and EPA-EA-Pn reduce the induction of the pro-inflammatory cytokine IL6-mRNA levels in the NR8383 cell line in response to LPS treatment. Rat macrophage NR8383 cells were stimulated with LPS (100 ng / mL) and treated with the indicated concentrations (10, 100, 500 and 1,000 nM) of DECA-EA-Pn and EPA-EA-Pn within less than 2 minutes after LPS. Cells were harvested 5 hours later, the time of the apparent peak of IL6-mRNA level induction after LPS. IL-6 mRNA levels were quantified by RT-qPCR. Results are expressed as the mean percentage of the levels measured in cells treated with LPS alone ± SEM (n=3) (compared to LPS alone: *: p<0.05; **: p<0.01; ***: p<0.001). [Figure 22]Figure 1. Effect of SYN-Pn and SYN on the resolution of inflammation in rat hippocampus after status epilepticus. Juveline (42 days old) male Sprague-Dawley rats were subjected to pilocarpine-induced status epilepticus (Pilo-SE) and treated with SYN (2 mg / kg; n=7) or SYN-Pn (2 mg / kg; n=7) 2 hours after the onset of SE. Untreated rats received NaCl (n=5) instead of SYN or SYN-Pn. Brains were collected 9 hours after SE, at the peak of the inflammatory response. Hippocampi were microdissected and mRNA levels were quantified by RT-qPCR. Data illustrate the variation for IL1β and TNFα mRNA and for the integrated index of both IL1β and TNFα. Results are expressed as the mean percentage ± SEM of the values measured in rats subjected to Pilo-SE and treated with NaCl (compared to Pilo-SE alone: *: p<0.05; **: p<0.01; ANOVA 1 followed by post-hoc Tukey's HSD test). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0040] As demonstrated by the inventors in the examples below, the present invention provides a new family of vectors that have significant structural flexibility, thereby allowing the delivery of biologically active compounds such as long-chain fatty acids of the omega-3 type. These vectors exhibit specific absorption kinetics and specific intestinal localization of absorption. They can deliver fatty acids with different structures and their metabolic derivatives, targeting several different molecular targets. More specifically, the inventors have demonstrated that metabolic derivatives resulting from hydrolysis of the compound of formula (I) of the present invention can inhibit key molecular inflammatory markers, prevent cognitive decline or deficits, and / or rescue or restore cognitive function in brain injury, traumatic brain injury and / or in neuroinflammatory disease and / or in neurodegenerative disease.
[0041] In accordance with the present invention, the following terms have the following definitions.
[0042] The term "alkyl chain" refers to a linear or branched, saturated or unsaturated hydrocarbon chain containing at least two carbon atoms, more particularly having from 10 to 24, from 12 to 18, from 12 to 16 carbon atoms, preferably 14 carbon atoms.
[0043] The term "alkyl" refers to a saturated or unsaturated, straight or branched chain aliphatic group. The term "(C1-C6)alkyl" refers to an alkyl group having from 1 to 6 carbon atoms, preferably 1, 2, 3, 4, 5 or 6 carbon atoms. In a preferred embodiment, the term "(C1-C6)alkyl" is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl or hexyl.
[0044] The term "fatty acyl" refers to one alkyl chain, as defined above, functionalized with an acyl group, in particular having 2 to 30 carbon atoms. The term "fatty acyl" also includes the corresponding carboxylic acid, in which the hydroxyl group of the carboxylic acid has been removed. Examples of "fatty acyl" or the corresponding carboxylic acid are, for example, acetic acid, propionic acid, butyric acid, valeric acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, lignoceric acid, myristoleic acid, palmitoleic acid, oleic acid, vaccenic acid, linoleic acid, alpha-linoleic acid, arachidonic acid, eicosapentaenoic acid, erucic acid and docosahexaenoic acid. Preferred "fatty acyl" or its corresponding carboxylic acid is capric acid, eicosapentaenoic acid or docosahexaenoic acid (DHA), more preferably docosahexaenoic acid (DHA).
[0045] The term "oxygen derivative" of a fatty acyl refers to a fatty acyl as defined above that is substituted with at least one hydroxyl group (-OH). Non-limiting examples of oxygen derivatives of fatty acyl include resolvins, maresins, neuroprotectins, and neuroprostanes.
[0046] The term "halogen" corresponds to one atom of fluorine, chlorine, bromine or iodine.
[0047] The term "hydrate" refers to a compound in hydrate form. In certain embodiments, the term "hydrate" includes hemihydrates, monohydrates, and polyhydrates.
[0048] The phrase "substituted by at least one" means that a group is substituted by one or several of the groups in the list.
[0049] "Pharmacologically acceptable salt" refers to a salt of the compounds of the present invention of formula (I), (I'), (I"), (II) and (II') that possesses the requisite biological activity. "Pharmaceutical salt" includes inorganic and organic acid salts. Representative examples of suitable inorganic acids include hydrochloric acid, hydrobromic acid, hydroiodic acid, phosphoric acid and the like. Representative examples of suitable organic acids include formic acid, acetic acid, trichloroacetic acid, trifluoroacetic acid, propionic acid, benzoic acid, cinnamic acid, citric acid, fumaric acid, maleic acid, methanesulfonic acid and the like. Further examples of pharmaceutical inorganic or organic acid addition salts include pharmaceutical salts listed in J. Pharm. Sci. 1977, 66, 2, as well as those listed in Handbook of Pharmaceutical Salts: Properties, Selection, and Use, edited by P. Heinrich Stahl and Camille G. Wermuth, 2002. "Pharmaceutical salt" also includes inorganic and organic base salts. Representative examples of suitable inorganic bases include alkaline earth metal salts, such as sodium or potassium salts, calcium or magnesium salts, or ammonium salts. Representative examples of suitable salts with organic bases include, for example, salts with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.
[0050] Compounds of formula (I) Thus, the present invention provides a compound of formula (I):
[0051] [ka]
[0052] [In the formula, n is an integer equal to 0 or 1, ○ A is A group of formula (A'):
[0053] [ka]
[0054] {In the formula, - R 1' is a saturated or unsaturated (C1-C6) alkyl group optionally substituted with at least one group selected from hydroxyl and halogen; 24 ) an alkyl chain, - R 2' represents hydrogen, a saturated or unsaturated fatty acyl containing from 2 to 30 carbon atoms, one of its oxygen derivatives, or a biologically active compound attached to the remainder of the molecule by an acyl group; or A group of formula (A"):
[0055] [ka]
[0056] {In the formula, - R 1" represents a preferably saturated fatty acyl containing from 2 to 30 carbon atoms, - R 2" represents hydrogen, a saturated or unsaturated fatty acyl containing from 2 to 30 carbon atoms, one of its oxygen derivatives, or a biologically active compound attached to the remainder of the molecule by an acyl group. represents a group selected from R3 represents hydrogen, a saturated or unsaturated fatty acyl containing from 2 to 30 carbon atoms, one of its oxygen derivatives, or a biologically active compound bound to the remainder of the molecule by an acyl group; R4 represents hydrogen or a (C1-C6) alkyl group. and its hydrates, or diastereoisomers, and / or pharmacologically acceptable salts.
[0057] In a preferred embodiment, R3 is not hydrogen.
[0058] Thus, preferably, the present invention provides a compound of formula (I):
[0059] [ka]
[0060] [In the formula, n is an integer equal to 0 or 1, ○ A is A group of formula (A'):
[0061] [ka]
[0062] {In the formula, - R 1' is a saturated or unsaturated (C1-C6) alkyl group optionally substituted with at least one group selected from hydroxyl and halogen; 24 ) an alkyl chain, - R 2' represents hydrogen, a saturated or unsaturated fatty acyl containing from 2 to 30 carbon atoms, one of its oxygen derivatives, or a biologically active compound attached to the remainder of the molecule by an acyl group; or A group of formula (A"):
[0063] [ka]
[0064] {In the formula, - R 1" represents a preferably saturated fatty acyl containing from 2 to 30 carbon atoms, - R 2"represents hydrogen, a saturated or unsaturated fatty acyl containing from 2 to 30 carbon atoms, one of its oxygen derivatives, or a biologically active compound attached to the remainder of the molecule by an acyl group. represents a group selected from R3 represents a saturated or unsaturated fatty acyl containing from 2 to 30 carbon atoms, one of its oxygen derivatives, or a biologically active compound bound to the remainder of the molecule by an acyl group; R4 represents hydrogen or a (C1-C6) alkyl group. and its hydrates, or diastereoisomers, and / or pharmacologically acceptable salts.
[0065] According to a particular embodiment of the invention, the compound of formula (I), (I′) or (I″) is 2' , R 2" and R3 is independently - Hydrogen, - saturated or unsaturated fatty acyls containing from 2 to 30 carbon atoms, selected from the group consisting of acetic acid, propionic acid, butyric acid, valeric acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, lignoceric acid, myristoleic acid, palmitoleic acid, oleic acid, vaccenic acid, linoleic acid, alpha-linoleic acid, arachidonic acid, eicosapentaenoic acid, erucic acid and docosahexaenoic acid, preferably docosahexaenoic acid, or - oxygen derivatives of saturated or unsaturated fatty acyls containing from 2 to 30 carbon atoms selected from resolvins, maresins, neuroprotectins and neuroprostanes; It is as if it represents:
[0066] According to another particular embodiment, the compound of formula (I), (I') or (I") is ○ R 2' and R 2" But independently, - Hydrogen, - saturated or unsaturated fatty acyls containing from 2 to 30 carbon atoms, selected from the group consisting of acetic acid, propionic acid, butyric acid, valeric acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, lignoceric acid, myristoleic acid, palmitoleic acid, oleic acid, vaccenic acid, linoleic acid, alpha-linoleic acid, arachidonic acid, eicosapentaenoic acid, erucic acid and docosahexaenoic acid, preferably docosahexaenoic acid, or - oxygen derivatives of saturated or unsaturated fatty acyls containing from 2 to 30 carbon atoms selected from resolvins, maresins, neuroprotectins and neuroprostanes; represents ○ R3 is - saturated or unsaturated fatty acyls containing from 2 to 30 carbon atoms, selected from the group consisting of acetic acid, propionic acid, butyric acid, valeric acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, lignoceric acid, myristoleic acid, palmitoleic acid, oleic acid, vaccenic acid, linoleic acid, alpha-linoleic acid, arachidonic acid, eicosapentaenoic acid, erucic acid and docosahexaenoic acid, preferably docosahexaenoic acid, or - oxygen derivatives of saturated or unsaturated fatty acyls containing from 2 to 30 carbon atoms selected from resolvins, maresins, neuroprotectins and neuroprostanes; It is as if it represents:
[0067] According to a further particular embodiment of the invention, the compound of formula (I), (I′) or (I″) is 2' , R 2" and R3 represents a biologically active compound linked to the remainder of the molecule by an acyl group.
[0068] As used herein, the term "biologically active compound" includes all compounds and all molecules that have biological activity, and more specifically, therapeutic activity.For example, biologically active compounds are anti-inflammatory compounds, neuroleptic compounds, antipsychotic compounds and anti-epileptic compounds, etc.According to certain embodiments, the biologically active compound is one of fatty acyl or its oxygenated derivatives, as described above.
[0069] According to this particular embodiment, the biologically active compound is linked to the rest of the molecule by one acyl group (-C=O). Preferably, the biologically active compound is naturally or chemically functionalized with a carbonyl or carboxyl group to form an amide bond (-NH-CO) between the vector and the biologically active compound. Preferably, the biologically active compound functionalized with a carbonyl or carboxyl group forms an amide bond with an amine group of the vector.
[0070] According to the invention, the compounds of formula (I) are such that R4 represents a hydrogen atom or a (C1-C6) alkyl group. Preferably, R4 represents a hydrogen atom or a methyl group, more preferably hydrogen.
[0071] The compounds of formula (I) as defined above can be classified into two subfamilies according to the chemical structure of group (A): sphingosynaptollipoxins (SSL) of formula (I') and aminoglycerophosphosynaptollipoxins (AGPSL) of formula (I").
[0072] Sphingosynaptollipoxin (SSL) SSL is a compound in which A is a group of formula (A'):
[0073] [ka]
[0074] [In the formula, - R 1'is a saturated or unsaturated (C1-C6) alkyl group optionally substituted with at least one group selected from hydroxyl and halogen; 24 ) an alkyl chain, - R 2' represents hydrogen, a saturated or unsaturated fatty acyl containing from 2 to 30 carbon atoms, one of its oxygen derivatives, or a biologically active compound attached to the remainder of the molecule by an acyl group. wherein R 1 is an integer from 1 to 2;
[0075] Thus, a particular embodiment of the present invention is an SSL compound of formula (I'):
[0076] [ka]
[0077] [In the formula, n is an integer equal to 0 or 1, ○ R 1' is a saturated or unsaturated (C1-C6) alkyl group optionally substituted with at least one group selected from hydroxyl and halogen; 24 ) an alkyl chain, ○ R 2' represents hydrogen, a saturated or unsaturated fatty acyl containing from 2 to 30 carbon atoms, one of its oxygen derivatives, or a biologically active compound bound to the remainder of the molecule by an acyl group; R3 represents hydrogen, a saturated or unsaturated fatty acyl containing from 2 to 30 carbon atoms, one of its oxygen derivatives, or a biologically active compound linked to the remainder of the molecule by an acyl group; preferably a saturated or unsaturated fatty acyl containing from 2 to 30 carbon atoms, one of its oxygen derivatives, or a biologically active compound linked to the remainder of the molecule by an acyl group, R4 represents hydrogen or a (C1-C6) alkyl group, preferably a methyl group. Regarding.
[0078] According to a preferred embodiment, R1' represents a saturated or unsaturated alkyl chain containing from 10 to 20, from 12 to 18, preferentially from 12 to 16 and even more preferably 14 carbon atoms, said chain being optionally substituted by at least one group selected from among hydroxyl and halogen. 1' represents a saturated alkyl chain containing 14 carbon atoms, ie, a tetradecanyl chain.
[0079] According to a further preferred embodiment, R 2' and R3 independently represents hydrogen or docosahexaenoic acid.
[0080] According to a further preferred embodiment, R4 represents hydrogen.
[0081] According to a particular embodiment, the compounds of formula (I') are such that n is an integer equal to 0. According to this embodiment, where n is 0, the compounds of formula (I') contain a phosphonate bond (CP) that allows the R3-NH-CH2-CH(R4)- group to be bonded to phosphorus. These compounds of formula (I') where n is equal to 0 correspond to the compounds SSL-X as disclosed herein.
[0082] Preferred compounds of the present invention are ○ n is an integer equal to 0, ○ R 1' represents a tetradecanyl group; ○ R 2' represents docosahexaenoic acid, R3 represents hydrogen; R4 represents hydrogen; The compound of formula (I') is SSL-X1.
[0083] Preferred compounds of the present invention are ○ n is an integer equal to 0, R1 represents a tetradecanyl group; ○ R 2' represents hydrogen, R3 represents docosahexaenoic acid, R4 represents hydrogen; The compound of formula (I') is SSL-X2.
[0084] Preferred compounds of the present invention are ○ n is an integer equal to 0, ○ R 1' represents a tetradecanyl group; ○ R 2' represents docosahexaenoic acid, R3 represents docosahexaenoic acid, R4 represents one hydrogen; The compound of formula (I') is SSL-X3.
[0085] Compounds SSL-X of formula (I') can be prepared by a bio-based approach and / or by a total chemical synthesis approach. The general procedure for preparing SSL compounds of formula (I') is illustrated in Figure 1.
[0086] In the context of a biobased approach, ceramide aminoethylphosphonate (CAEP) is extracted and purified from marine mollusks such as the mussel Mytilus galloprovincialis, an organism that is abundant and not expensive compared to other marine mollusks. To achieve this, total lipids are extracted and purified according to the Folch method (Folch J., Lees M. and Stanley GHS; (1957); A simple method for the isolation and purification of total lipids from animal tissues. J. Biol. Chem. 226, 497-509) and then saponified. After purification of the unsaponifiable fraction, CAEP is deacylated either by strong alkaline hydrolysis or by acid hydrolysis. The deacylated CAEP is then purified, aliquoted and reacted with defined amounts of docosahexaenoic acid to obtain the compounds SSL-X1, SSL-X2 and SSL-X3 by N-acylation.
[0087] In the context of a total chemical synthesis approach, the first step is the acetylation of the hydroxyl groups of commercially available sphingomyelin, for example using acetic anhydride, to obtain O-acetylated sphingomyelin. The second step is the hydrolysis of O-acetylated sphingomyelin with a nonspecific C-type phospholipase (Clostridium perfringens) to obtain O-acetylated ceramide, which is then purified. The third step is the phosphonylation of O-acetylated ceramide with monochlorinated 2-phthalimidophosphonic acid to obtain O-acetylated ceramide-(2-phthalimidoethyl)-phosphonate. The fourth step is the hydrazinolysis of O-acetylated ceramide-(2-phthalimidoethyl)-phosphonate to obtain O-acetylated sphingosylphophonoethanolamine, which is then purified. The O-acetylated sphingosylphosphoethanolamine is then reacted with an amount of DHA to provide compounds SSL-X1, SSL-X2 and SSLX3 by N-acylation followed by O-deacylation.
[0088] According to a further particular embodiment, the compounds of formula (I') are such that n is an integer equal to 1. According to this embodiment where N is 1, the compounds of formula (I') contain an ester-phosphorus bond (OP) that allows the attachment of the R3-NH-CH2-CH(R4)-O- group to phosphorus. These compounds of formula (I') where n is equal to 1 correspond to compound SSL-Y as disclosed herein.
[0089] Preferred compounds of the present invention are ○ n is an integer equal to 1, ○ R 1' represents a tetradecanyl group; ○ R 2' represents docosahexaenoic acid, R3 represents hydrogen; R4 represents hydrogen; The compound of formula (I') is SSL-Y1.
[0090] Preferred compounds of the present invention are ○ n is an integer equal to 1, ○ R 1' represents a tetradecanyl group; ○ R 2' represents hydrogen, R3 represents docosahexaenoic acid, R4 represents one hydrogen; The compound of formula (I') is SSL-Y2.
[0091] Preferred compounds of the present invention are ○ n is an integer equal to 1, ○ R 1' represents a tetradecanyl group; ○ R 2' represents docosahexaenoic acid, R3 represents docosahexaenoic acid, R4 represents hydrogen; The compound of formula (I') is SSL-Y3.
[0092] Compounds SSL-Y1, SSL-Y2 and SSL-Y3 can be synthesized by a total chemical synthesis approach starting from ceramide phosphorylethanolamine (CPEA) as a commercially available starting material and following the process illustrated in Figure 1, including the deacylation, purification, dosage and N-acylation steps of the process.
[0093] Aminoglycerophosphosynaptolipoxin (AGPSL) AGPSL is a compound in which A is a group of formula (A"):
[0094] [ka]
[0095] [In the formula, - R 1"represents a preferably saturated fatty acyl containing from 2 to 30 carbon atoms, - R 2" represents hydrogen, a saturated or unsaturated fatty acyl containing from 2 to 30 carbon atoms, one of its oxygen derivatives, or a biologically active compound attached to the remainder of the molecule by an acyl group. wherein R 1 is an integer from 1 to 2;
[0096] Thus, a further particular embodiment of the present invention is an AGPSL compound of formula (I"):
[0097] [ka]
[0098] [In the formula, n is an integer equal to 0 or 1, ○ R 1" represents a preferably saturated fatty acyl containing from 2 to 30 carbon atoms, ○ R 2" represents hydrogen, a saturated or unsaturated fatty acyl containing from 2 to 30 carbon atoms, one of its oxygen derivatives, or a biologically active compound bound to the remainder of the molecule by an acyl group; R3 represents hydrogen, a saturated or unsaturated fatty acyl containing from 2 to 30 carbon atoms, one of its oxygen derivatives, or a biologically active compound linked to the remainder of the molecule by an acyl group, preferably a saturated or unsaturated fatty acyl containing from 2 to 30 carbon atoms, one of its oxygen derivatives, or a biologically active compound linked to the remainder of the molecule by an acyl group, R4 represents hydrogen or a (C1-C6) alkyl group, preferably a methyl group. Regarding.
[0099] According to a preferred embodiment, R 1"represents a preferably saturated fatty acyl containing from 12 to 20 carbon atoms, preferably from 12 to 18 carbon atoms, preferably from 12 to 16 carbon atoms, more preferably 16 carbon atoms. 1" represents palmitic acid.
[0100] According to a further preferred embodiment, R 2" and R3 independently represents hydrogen or docosahexaenoic acid.
[0101] According to a further preferred embodiment, R4 represents hydrogen.
[0102] According to a particular embodiment, the compounds of formula (I") are such that n is an integer equal to 0. According to this embodiment, where n is 0, the compounds of formula (I") contain a phosphonate bond (CP) that allows the attachment of the R3-NH-CH2-CH(R4)- group to phosphorus. These compounds of formula (I") where n is equal to 0 correspond to the compound AGPSL-X as disclosed herein.
[0103] Preferred compounds of the present invention are ○ n is an integer equal to 0, ○ R 1" represents palmitic acid, ○ R 2" represents docosahexaenoic acid, R3 represents hydrogen; R4 represents hydrogen; The compound of formula (I") is AGPSL-X1.
[0104] Preferred compounds of the present invention are ○ n is an integer equal to 0, ○ R 1" represents palmitic acid, ○ R 2" represents hydrogen, R3 represents docosahexaenoic acid, R4 represents hydrogen; The compound of formula (I") is AGPSL-X2.
[0105] Preferred compounds of the present invention are ○ n is an integer equal to 0, ○ R 1" represents palmitic acid, ○ R 2" represents docosahexaenoic acid, R3 represents docosahexaenoic acid, R4 represents one hydrogen; The compound of formula (I") is AGPSL-X3.
[0106] AGPSL-X can be prepared by a total chemical synthesis approach. In this context, the first step is phosphorylation of commercially available diacylglycerol using 2-monochlorinated phthalimidophosphonic acid to obtain diacylglycerol-(2-phthalimidoethyl)-phosphonate. The second step is hydrazinolysis of diacylglycerol-(2-phthalimidoethyl)phosphonate to obtain glycerophosphonoethanolamine, which is then purified. Glycerophosphonoethanolamine is then reacted with an amount of DHA to provide compound AGPSL-X2 by N-acylation. AGPSL-X1 is obtained by deacylation of glycerophosphonoethanolamine with phospholipase A2 and re-O-acylation in the presence of DHA. AGPSL-X3 is obtained by deacylation of AGPSL-X1 at the sn-2 position of glycerol and re-O-acylation in the presence of DHA.
[0107] According to a further particular embodiment, the compounds of formula (I") are such that n is an integer equal to 1. According to this embodiment, where n is 1, the compounds of formula (I") comprise an ester-phosphorus bond (OP) that allows the attachment of the R3-NH-CH2-CH(R4)-O- group to phosphorus. These compounds of formula (I") where n is equal to 1 correspond to the compound AGPSL-Y as disclosed herein.
[0108] Preferred compounds of the present invention are ○ n is an integer equal to 1, ○ R 1" represents palmitic acid, ○ R 2" represents docosahexaenoic acid, R3 represents hydrogen; R4 represents hydrogen; The compound of formula (I") is AGPSL-Y1.
[0109] Preferred compounds of the present invention are ○ n is an integer equal to 1, ○ R 1" represents palmitic acid, ○ R 2" represents hydrogen, R3 represents docosahexaenoic acid, R4 represents hydrogen; The compound of formula (I") is AGPSL-Y2.
[0110] Preferred compounds of the present invention are ○ n is an integer equal to 1, ○ R 1" represents palmitic acid, ○ R 2" represents docosahexaenoic acid, R3 represents docosahexaenoic acid, R4 represents hydrogen; The compound of formula (I") is AGPSL-Y3.
[0111] AGPSL-Y can be prepared by a total chemical synthesis approach starting from commercially available phosphatidylethanolamine. AGPSL-Y1 is obtained by deacylation of phosphatidylethanolamine at the sn-2 position of glycerol by phospholipase A2 and by re-O-acylation in the presence of DHA. AGPSL-Y2 is obtained by deacylation of phosphatidylethanolamine at the sn-2 position of glycerol by phospholipase A2 and by N-acylation in the presence of DHA. AGPSL-Y3 is obtained by deacylation of phosphatidylethanolamine at the sn-2 position of glycerol by phospholipase A2 and by N- and O-acylation in the presence of docosahexaenoic acid.
[0112] Compound of formula (II) The present invention further relates to a compound of formula (II): R5-NH-CH2-CH(R7)-O (n) -R6(II) [In the formula, n is an integer equal to 0 or 1, R5 represents a saturated or unsaturated fatty acyl containing from 2 to 30 carbon atoms or one of its oxygen derivatives, ○ R6 is -PO3 2- It is based on R7 represents hydrogen or a (C1-C6) alkyl group; With the proviso that when n is equal to 1, R5 is not arachidonic acid; and It relates to a hydrate, or a diastereoisomer, or a pharmacologically acceptable salt thereof.
[0113] According to a particular embodiment of the invention, the compound of formula (II) is one in which R5 is saturated or unsaturated fatty acyls containing from 2 to 30 carbon atoms, selected from the group consisting of acetic acid, propionic acid, butyric acid, valeric acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, lignoceric acid, myristoleic acid, palmitoleic acid, oleic acid, vaccenic acid, linoleic acid, alpha-linoleic acid, arachidonic acid, eicosapentaenoic acid, erucic acid and docosahexaenoic acid, preferably capric acid, eicosapentaenoic acid and docosahexaenoic acid, or - oxygen derivatives of saturated or unsaturated fatty acyls containing from 2 to 30 carbon atoms selected from resolvins, maresins, neuroprotectins and neuroprostanes; It is as if it represents:
[0114] In a preferred embodiment of the invention, the compound of formula (II) is such that R5 represents a saturated or unsaturated fatty acyl containing from 2 to 30 carbon atoms, which is docosahexaenoic acid.
[0115] According to the invention, the compounds of formula (II) are such that R7 represents hydrogen or a (C1-C6) alkyl group. Preferably, R7 represents a hydrogen atom or a methyl group, more preferably hydrogen.
[0116] The compounds of formula (II) as defined above may be classified into two subfamilies according to the integer n: ethanolamine-phosphonate derivatives of fatty acids and ethanolamine-phosphate derivatives of fatty acids.
[0117] Ethanolamine-phosphonate derivatives In certain embodiments, the compound of formula (II) is such that n is equal to 0. Such certain compounds may be referred to herein as "ethanolamine-phosphonate derivatives of fatty acids."
[0118] According to this particular embodiment, the compound of formula (II) has the following formula (IIA): R5-NH-CH2-CH(R7)-PO32- (IIA) [In the formula, R5 and R7 are as defined above.] It can also be expressed by:
[0119] In a preferred embodiment, the compound of formula (IIA) is such that R5 represents a saturated or unsaturated fatty acyl containing from 2 to 30 carbon atoms selected from among capric acid, eicosapentaenoic acid and docosahexaenoic acid.
[0120] In a further preferred embodiment, the compounds of formula (IIA) are such that R7 represents hydrogen.
[0121] In a more preferred embodiment, the compound of formula (IIA) is such that R5 represents capric acid, eicosapentaenoic acid or docosahexaenoic acid, and R7 represents hydrogen.
[0122] In an even more preferred embodiment, the compound of formula (IIA) is such that R5 represents docosahexaenoic acid and R7 represents hydrogen.
[0123] Ethanolamine-phosphate derivatives In certain embodiments, the compound of formula (II) is such that n is equal to 1. Such certain compounds may be referred to herein as "ethanolamine-phosphate derivatives of fatty acids."
[0124] According to this particular embodiment, the compound of formula (II) has the following formula (IIB): R5-NH-CH2-CH(R7)-O-PO3 2- (IIB) wherein R5 and R7 are as defined above, with the proviso that R5 is not arachidonic acid. It can also be expressed by:
[0125] In a further particular embodiment, the compound of formula (IIB) is such that R5 represents a saturated or unsaturated fatty acyl containing from 2 to 30 carbon atoms selected from among the saturated or unsaturated fatty acyl containing from 2 to 30 carbon atoms selected from the group consisting of acetic acid, propionic acid, butyric acid, valeric acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, lignoceric acid, myristoleic acid, palmitoleic acid, oleic acid, vaccenic acid, linoleic acid, alpha-linoleic acid, eicosapentaenoic acid, erucic acid and docosahexaenoic acid, preferably capric acid, eicosapentaenoic acid and docosahexaenoic acid.
[0126] In a preferred embodiment, the compound of formula (IIB) is such that R5 represents a saturated or unsaturated fatty acyl containing from 2 to 30 carbon atoms selected from among capric acid, eicosapentaenoic acid and docosahexaenoic acid.
[0127] In a further preferred embodiment, the compounds of formula (IIB) are such that R7 represents hydrogen.
[0128] In a more preferred embodiment, the compound of formula (IIB) is such that R5 represents capric acid, eicosapentaenoic acid or docosahexaenoic acid, and R7 represents hydrogen.
[0129] In an even more preferred embodiment, the compound of formula (IIB) is such that R5 represents docosahexaenoic acid and R7 represents hydrogen.
[0130] Ethanolamine Derivatives Further disclosed herein is a compound of formula (II'): R 5' -NH-CH2-CH(R 7' )-O (n) -R 6' (II') [In the formula, ○ n is an integer equal to 1, ○ R 5'represents a saturated or unsaturated fatty acyl containing from 2 to 30 carbon atoms or one of its oxygen derivatives, ○ R 6' is hydrogen, ○ R 7' represents hydrogen or a (C1-C6) alkyl group, and A hydrate, or a diastereoisomer, or a pharmacologically acceptable salt thereof.
[0131] Certain such compounds may be referred to herein as "ethanolamine derivatives of fatty acids."
[0132] The compound of formula (II) has the following formula (IIC): R5-NH-CH2-CH(R7)-OH(IIC) [In the formula, R5 and R7 are as defined above.] It can also be expressed by:
[0133] In a preferred embodiment, the compound of formula (IIC) is such that R5 represents a saturated or unsaturated fatty acyl containing from 2 to 30 carbon atoms selected from among capric acid, eicosapentaenoic acid and docosahexaenoic acid.
[0134] In a further preferred embodiment, the compounds of formula (IIC) are such that R7 represents hydrogen.
[0135] In a more preferred embodiment, the compound of formula (IIC) is such that R5 represents capric acid, eicosapentaenoic acid or docosahexaenoic acid, and R7 represents hydrogen.
[0136] In an even more preferred embodiment, the compound of formula (IIC) is such that R5 represents docosahexaenoic acid and R7 represents hydrogen.
[0137] Purpose As disclosed above, the compounds according to the present invention of formula (I), including the compounds of formula (II), including the compounds of formula (I') and (I") and of formula (IIA) and (IIB), may be used as drugs or medicines. The compounds according to the present invention of formula (I), including the compounds of formula (II), including the compounds of formula (I') and (I") and of formula (IIA) and (IIB), may be used in the prevention and / or treatment of inflammatory diseases. The compounds according to the invention of formula (I), including compounds of formula (II), including compounds of formula (IIA) and (IIB), of formula (I') and (I"), may be used to prevent cognitive decline / deficits and / or to restore cognitive function altered in brain injury and / or in traumatic brain injury and / or in neuroinflammatory diseases and / or in neurodegenerative diseases. In a further particular embodiment of the invention, the compounds of formula (I), (I'), (I"), (II), (IIA), (IIB) and (II') according to the invention may be used to prevent and / or treat diseases involving seizures. In a further particular embodiment of the invention, the compounds of formulae (I), (I'), (I"), (II), (IIA), (IIB) and (II') according to the invention may be used as antiepileptic drugs. In a further particular embodiment of the invention, the compounds of formulae (I), (I'), (I"), (II), (IIA), (IIB) and (II') according to the invention may be used to protect cognitive function during non-pathological ageing. In a further particular embodiment of the invention, the compounds of formulae (I), (I'), (I"), (II), (IIA), (IIB) and (II') according to the invention may be used to enhance cognitive function in healthy subjects.
[0138] As used herein, the terms "treatment", "treat" and "treating" refer to the amelioration, prevention or reversal of a disease or disorder, such as an inflammatory disease or cognitive disorder, in a subject. In one embodiment, the terms "treatment", "treat" and "treating" can also refer to the inhibition or delay of progression of a disease or disorder in a subject. In another embodiment, these terms refer to the delay of onset of a disease or disorder in a subject. In some embodiments, the compounds of the invention are administered as a preventative measure. In this context, the terms "treatment" and "treating" can correspond to the terms "prevention" and "preventing", which refer to the reduction of the risk of acquiring a specified disease or disorder in a subject.
[0139] As used herein, the term "enhancing / enhancing cognitive function" refers to improving abilities such as attention, concentration, learning or memory in healthy subjects.
[0140] As used herein, a "subject" corresponds to any healthy organism, or an organism likely to suffer from an inflammatory disease and / or a disease and / or behavioral disorder involving cognitive impairment, and / or likely to have been subjected to a brain injury or traumatic brain injury. In a preferred embodiment, the subject is a mammal, preferably a human.
[0141] Without any specific mechanism of action, the compound of formula (I) can carry / deliver molecules with anti-inflammatory and / or anti-epileptic properties and / or with cognitive protection and repair properties.For example, the compound of formula (I) can carry fatty acid (or its metabolic derivatives), and thereby deliver either fatty acid, its ethanolamine derivative, or its ethanolamine-phosphonate derivative, or its ethanolamine-phosphate derivative in vivo.For example, when the compound of formula (I) carries docosahexaenoic acid, they can deliver either DHA and / or synaptamide and / or synaptamide phosphonate and / or phosphorylated synaptamide in vivo.As used herein, the term "synaptamide" corresponds to "DHA-ethanolamine".
[0142] The anti-inflammatory properties of the compounds of the present invention make them of great interest in the treatment of neurodegenerative diseases with a significant neuroinflammatory component. These properties also make these compounds effective in the treatment of various inflammatory diseases other than neurodegenerative diseases.
[0143] Thus, an object of the present invention relates to a compound of formula (I), (I'), (I") or (II) as defined herein for use as a medicament. A further object of the present invention is a pharmaceutical composition comprising at least one compound of the present invention of formula (I), (I'), (I") or (II) as defined herein and an acceptable pharmaceutical excipient. Also disclosed is a pharmaceutical composition comprising at least one compound of the present invention of formula (II') as defined herein and an acceptable pharmaceutical excipient.
[0144] According to certain embodiments, the pharmaceutical compositions of the invention comprising a compound of formula (I), (I'), (I") or (II) are used to prevent and / or treat inflammatory diseases, including, for example, inflammatory diseases of the central nervous system (neuroinflammatory diseases), inflammatory diseases of the retina, inflammatory joint diseases and inflammatory diseases of the digestive system.
[0145] Neuroinflammatory diseases are characterized by inflammation in the central nervous system (CNS), including the brain, spinal cord, and retina. The signs and symptoms of neuroinflammatory diseases can vary depending on the affected part of the CNS. Inflammation of the CNS or retina can cause focal disorders such as stroke, paresthesia, blindness, speech disorder, memory loss, reduced mental agility, and changes in concentration and behavior.
[0146] CNS inflammation can also cause psychiatric symptoms such as hallucinations, distorted thinking, mental confusion and mood swings. Depending on the extent and location of inflammation in the CNS, epileptic seizures and headaches may occur frequently. Epilepsy, Alzheimer's disease, Parkinson's disease, multiple sclerosis, dementia and Huntington's disease are non-exhaustive examples of neuroinflammatory diseases.
[0147] Inflammatory diseases of the digestive system are characterized by hyperactivity of the digestive immune system in the walls of parts of the digestive tract. Crohn's disease, ulcerative colitis and bowel syndrome are non-exhaustive examples of inflammatory diseases of the digestive system.
[0148] Inflammatory joint diseases are characterized by inflammation in the joints. Arthritis and rheumatism are non-exhaustive examples of inflammatory joint diseases.
[0149] In a further particular embodiment, the pharmaceutical compositions of the present invention comprising a compound of formula (I), (I'), (I"), (II) or (II') are used for preventing and / or treating diseases associated with cognitive impairment. Cognitive impairment refers to mental disorders that specifically affect memory, attention and adaptation. The causes of cognitive impairment vary between different types of disorders, but most of them are caused by brain damage. Alzheimer's disease, Parkinson's disease, Huntington's disease, epilepsy, delirium, dementia and memory loss are non-exhaustive examples of diseases associated with cognitive impairment.
[0150] In a further particular embodiment, the pharmaceutical compositions of the invention comprising a compound of formula (I), (I'), (I"), (II) or (II') are used to prevent and / or treat disorders associated with seizures. "Seizures" can be caused by paroxysmal changes in neurological function caused by excessive hypersynchronous discharge of neurons in the brain. Examples of disorders associated with seizures are epilepsy, a state of recurrent unprovoked seizures, and any reversible disorder that triggers (provokes) brain stimulation leading to seizures, such as infections, strokes, head injuries or reactions to drugs. In children, fever can trigger non-epileptic seizures (also called "febrile seizures"). Certain psychiatric disorders can cause symptoms that resemble seizures, called psychogenic non-epileptic seizures or pseudo-seizures.
[0151] The present invention therefore relates to a pharmaceutical composition comprising a compound of formula (I), (I'), (I") or (II) as defined herein for use for preventing and / or treating an inflammatory disease, in particular a disease selected from among inflammatory or neuroinflammatory diseases of the central nervous system, inflammatory diseases of the gastrointestinal tract, inflammatory diseases of the retina, inflammatory joint diseases. The present invention therefore further relates to a pharmaceutical composition comprising a compound of formula (I), (I'), (I"), (II) or (II') as defined herein for use for preventing and / or treating a disease associated with cognitive impairment.
[0152] The present invention also relates to a method for treating an inflammatory disease, in particular a disease selected from among inflammatory or neuroinflammatory diseases of the central nervous system, inflammatory diseases of the gastrointestinal tract, inflammatory joint diseases, inflammatory diseases of the retina or diseases involving cognitive impairment, comprising the step of administering to a subject in need thereof an effective amount of a compound of formula (I) or (II) or a pharmaceutical composition comprising such a compound.
[0153] The present invention also relates to the use of a compound of formula (I) or (II) for preparing a pharmaceutical composition for the treatment of an inflammatory disease, in particular an inflammatory or neuroinflammatory disease of the central nervous system, an inflammatory disease of the gastrointestinal tract, an inflammatory joint disease, an inflammatory disease of the retina or a disease involving cognitive impairment.
[0154] In certain embodiments of the invention, the disease / disorder prevented and / or treated by the compounds of formula (I), (I'), (I"), (II) or (II') is selected from epilepsy, traumatic brain injury, Alzheimer's disease, Parkinson's disease, multiple sclerosis, Crohn's disease, bowel syndrome, dementia and Huntington's disease, preferably epilepsy.
[0155] An object of the present invention is a pharmaceutical composition as defined herein comprising a compound of formula (I), (I'), (I"), (II) and (II') for use in preventing and / or treating a disease selected from the group consisting of epilepsy, traumatic brain injury, Alzheimer's disease, Parkinson's disease, multiple sclerosis, Crohn's disease, bowel syndrome, dementia and Huntington's disease. A further object of the present invention is a method for treating such a disease, comprising administering to a subject in need thereof a pharmaceutical composition as defined herein comprising a compound of formula (I), (I'), (I"), (II) and (II'). A further object of the present invention is the use of a compound of formula (I), (I'), (I"), (II) and (II') for the manufacture of a pharmaceutical composition for preventing and / or treating such a disease.
[0156] As used herein, "epilepsy" refers to epilepsy with focal awareness-preserving seizures, or with focal awareness-impaired seizures, or with bilateral tonic-clonic seizures, or with absence seizures, or with atypical absence seizures, or with tonic-clonic seizures, or with atonic seizures, or with clonic seizures, or with tonic seizures, or with myoclonic seizures, or with laughing and crying seizures, or with febrile seizures, or with refractory seizures, as well as autosomal dominant nocturnal frontal lobe epilepsy, childhood absence epilepsy, childhood epilepsy with centrotemporal spikes, also known as benign rolandic epilepsy, Doze syndrome, Dravet syndrome, early myoclonic encephalopathy, migratory focal seizures This category includes a variety of epilepsy syndromes, including: infantile epilepsy with generalized tonic-clonic seizures only, epilepsy with myoclonic absence seizures, epilepsy with continuous spike-and-wave pattern during sleep, frontal lobe epilepsy, infantile spasms (West syndrome) and tuberous sclerosis complex, juvenile absence epilepsy, juvenile myoclonic epilepsy, Lafora progressive myoclonic epilepsy, Landau-Kleffner syndrome, Lennox-Gastaut syndrome, Ohtahara syndrome, Panayiopoulus syndrome, progressive myoclonic epilepsy, reflex epilepsy and temporal lobe epilepsy.
[0157] A particular object of the present invention is a pharmaceutical composition as defined herein comprising a compound of formula (I), (I'), (I"), (II) and (II') for use for reducing / reducing the severity and / or frequency of epileptic seizures. A further particular object of the present invention is a method for reducing / reducing the severity and / or frequency of epileptic seizures, comprising administering to a subject in need thereof a pharmaceutical composition as defined herein comprising a compound of formula (I), (I'), (I"), (II) and (II'). A further particular object of the present invention is the use of a compound of formula (I), (I'), (I"), (II) and (II') for the manufacture of a pharmaceutical composition for reducing / reducing the severity and / or frequency of epileptic seizures.
[0158] In a further particular embodiment, the present invention relates to a pharmaceutical composition as defined herein for use to prevent cognitive decline / deficit and / or to restore cognitive function altered in brain injury and / or in traumatic brain injury and / or in neuroinflammatory diseases and / or in neurodegenerative diseases.
[0159] Certain embodiments of the present invention relate to a method for restoring cognitive functions altered in brain injury and / or in traumatic brain injury and / or in neuroinflammatory and / or in neurodegenerative diseases, comprising administering to a subject in need thereof an effective amount of a compound of formula (I), (I'), (I"), (II) or (II') or a pharmaceutical composition comprising such a compound.
[0160] A further particular embodiment of the present invention relates to the use of a compound of formula (I), (I'), (I"), (II) or (II') for the manufacture of a pharmaceutical composition for preventing cognitive decline or restoring cognitive functions altered in brain injury and / or in traumatic brain injury and / or in neuroinflammatory diseases and / or in neurodegenerative diseases.
[0161] As used herein, "cognitive function" refers to all mental functions related to knowledge, including executive function, learning and memory, attention and processing speed, language, among others.
[0162] As used herein, brain injury includes brain injury that originates from internal or external sources. A specific brain injury from external sources is "traumatic brain injury", which refers to craniocerebral trauma, including head injury or head and brain injury. Clinically, there are three main categories of traumatic brain injury: mild (no loss of consciousness or skull fracture), moderate (with initial loss of consciousness for more than a few minutes or with skull fracture) and severe (with immediate coma and without or with associated skull fracture). Among the many sequelae of traumatic brain injury, cognitive dysfunction may be the most important in relation to its contribution to long-term dysfunction.
[0163] Neurodegenerative diseases are disabling chronic diseases with slow and discontinuous evolution, in which an inflammatory component contributes to the pathogenesis. Neurodegenerative diseases also result in loss or alteration of cognitive functions. Spinocerebellar degeneration, multiple system atrophy, Alexander disease, Alper's disease, Alzheimer's disease, dementia with Lewy bodies, Creutzfeld's disease, Huntington's disease, Parkinson's disease, Pick's disease, progressive supranuclear palsy, and amyotrophic lateral sclerosis are non-exhaustive examples of neurodegenerative diseases.
[0164] According to further particular embodiments, the present invention relates to the use of a pharmaceutical composition as defined herein for preventing and / or preserving cognitive function during ageing and / or for enhancing cognitive function in healthy subjects.
[0165] Certain embodiments of the present invention relate to a method for preserving cognitive function during aging and / or enhancing cognitive function in a healthy subject, comprising administering to said healthy subject an effective amount of a compound of formula (I), (I'), (I"), (II) or (II') or a pharmaceutical composition comprising such a compound. As used herein, "preserving cognitive function" also means reducing the risk of alteration of cognitive function.
[0166] According to the present invention, the pharmaceutical composition as defined herein comprises a pharma- ceutically acceptable support or carrier. A "pharma-ceutically acceptable support" comprises a support that contains at least one acceptable pharmaceutical excipient. A "pharma-ceutically acceptable excipient" comprises any excipient that allows the pharmaceutical composition of the present invention to be formulated in the desired galenic form without inducing adverse effects on the treated subject. Those skilled in the art can select the nature and proportion of the pharma-ceutically acceptable excipient according to the formulation adapted to the intended administration route.
[0167] As used herein, "effective amount" or "effective dose" determines the amount or quantity of the compound of the present invention or the pharmaceutical composition containing the compound of the present invention that allows obtaining sufficient therapeutic effect for treating and / or preventing inflammatory disease or disease characterized by cognitive deficit. It is understood that the dosage can be adapted by those skilled in the art according to the patient, pathology, mode of administration, severity of disease, etc. For example, the effective amount of the compound of the present invention of formula (I), (I'), (I"), (II) or (II') is between 0.01 mg / kg and 100 mg / kg (BW), between 0.01 mg / kg and 50 mg / kg (BW), between 0.01 mg / kg and 10 mg / kg (BW). In particular, the effective amount of the compound of the present invention of formula (I), (I'), (I"), (II) or (II') is 5 mg / kg (BW), 10 mg / kg (BW) or 50 mg / kg (BW). This effective amount may be taken by the patient only once, or occasionally, such as once a week, twice a week, or three times a week, or more frequently, such as one or more times a day, for example, two or three times a day. Preferably, this amount is administered to the subject daily, i.e., once a day.
[0168] According to a preferred embodiment, the compounds of formula (I), (I'), (I"), (II) or (II') of the present invention are administered to a subject in an amount or dose of between 0.01 mg / kg and 100 mg / kg (BW), preferably between 0.01 mg / kg and 10 mg / kg (BW), more preferably about 5 mg / kg (BW), 10 mg / kg (BW) or 50 mg / kg (BW). In certain aspects, the compounds and pharmaceutical compositions of the present invention may be administered several days a week, such as 4, 5, 6 or 7 days. Preferably, they are administered once a day.
[0169] The route of administration of the pharmaceutical composition of the present invention may be oral or parenteral (including subcutaneous, intramuscular, intraperitoneal, intracerebroventricular, intravenous and / or intradermal). Preferably, the route of administration is parenteral, oral or topical. In the context of parenteral injection, intravenous injection is preferred.
[0170] According to a preferred embodiment, the pharmaceutical compositions containing the compounds of formula (I) are to be administered orally.
[0171] According to a further preferred embodiment, the pharmaceutical composition comprising the compound of formula (II) or (II') is to be administered by oral route or by parental route. The preferred parenteral route is the intraperitoneal route.
[0172] As described in the examples, the SSL corresponding to the compound of formula (I') exhibits slow and prolonged intestinal hydrolysis / absorption, whereas the glycerophospholipid AGPSL corresponding to the compound of formula (I") is relatively fast hydrolyzed / absorbed in the intestinal tract (Digestion of Phospholipids after Secretion of Bile into the Duodenum Changes the Phase Behavior of Bile Components. Woldeamanuel A. Birru. et al., Mol. Pharmaceutics, 2014, 11, 2825-2834). These pharmacokinetic differences introduce a number of potential advantages and allow the treatment of patients either in an acute or chronic manner, thereby offering many possibilities for therapeutic intervention according to clinical cases. For chronic treatments, oral administration of a pharmaceutical composition comprising a compound of formula (I') is preferred. For acute treatments, oral administration of a pharmaceutical composition comprising a compound of formula (I") is preferred.
[0173] In therapeutic emergency situations such as traumatic brain injury and status epilepticus, intravenous, intracerebroventricular or subcutaneous administration of metabolic derivatives of fatty acids as described herein, in particular metabolic derivatives of docosahexaenoic acid such as synaptamide, synaptamide phosphate and synaptamide phosphonate, may be considered.
[0174] Thus, a further object relates to a pharmaceutical composition comprising at least one metabolic derivative of docosahexaenoic acid, in particular synaptamide, synaptamide phosphate and / or synaptamide phosphonate, for protecting and / or restoring cognitive function altered by traumatic brain injury and / or status epilepticus, wherein said pharmaceutical composition is administered intravenously.
[0175] A further object relates to a method for protecting and / or restoring cognitive function altered by traumatic brain injury and / or status epilepticus in a subject, comprising the intravenous administration to said subject of an effective amount or dose of at least one metabolic derivative of docosahexaenoic acid, in particular synaptamide, synaptamide phosphate and / or synaptamide phosphonate, or a pharmaceutical composition comprising same.
[0176] Another object relates to the use of at least one metabolic derivative of docosahexaenoic acid, in particular synaptamide, synaptamide phosphate and / or synaptamide phosphonate, for the manufacture of a pharmaceutical composition for protecting and / or restoring cognitive function altered by traumatic brain injury and / or status epilepticus, wherein said pharmaceutical composition is administered intravenously.
[0177] According to a preferred embodiment, at least one of the metabolic derivatives of docosahexaenoic acid, in particular synaptamide, synaptamide phosphate and / or synaptamide phosphonate, is administered intravenously to a subject at a dose ranging from 0.01 to 10 mg / kg (BW), preferably from 0.5 to 5 mg / kg (BW), more preferably at a dose of about 2 mg / kg (BW).
[0178] According to another embodiment, the compounds of the present invention of formula (I), including compounds of formula (I') and (I"), and compounds of the present invention of formula (II), including compounds of formula (IIA) and (IIB), as defined herein, may be used as dietary supplements.
[0179] Further aspects and advantages of the present invention are disclosed in the following examples, which should be construed as illustrative and not as limiting the scope of this application. EXAMPLES
[0180] Example A synthesis I.1. Synthesis of SSL-X compound (n=0) 1. Bio-based approaches The synthesis of SSL-X was carried out using the relative abundance of ceramide aminoethylphosphonate (CAEP) in some marine organisms, especially bivalve mollusks such as the mussel Mytilus galloprovincialis. To do so, total lipids were extracted and purified according to the Folch method (Folch J., Lees M. and Stanley GHS; (1957); A simple method for the isolation and purification of total lipids from animal tissues. J. Biol. Chem. 226, 497-509). The lipids were then saponified. After purification of the lipid fraction that was not saponified, CAEP was deacylated using either strong alkaline or acid hydrolysis. The deacylated CAEP was then purified and quantified. SSL-X1, SSL-X2 and SSL-X3 were then synthesized by N-acylation. Figure 1 illustrates the synthesis procedure.
[0181] After this, the detailed procedure for synthesis of SSL is described.
[0182] 1.1. Total lipid extraction and purification. Total lipids are extracted and purified according to the Folch method. To do so, tissues are homogenized using a Polytron (25 mL / g tissue) in a chloroform-methanol (2:1, v / v) mixture. Lipid extraction is allowed to proceed for 12 hours at 4° C. Samples are filtered using an ashless filter and lipids are purified using phase partitioning as follows:
[0183] The first wash of the crude lipid extract is carried out using a 0.25% aqueous KCl solution (m / v), which is added to the lipid extract in a proportion of one-fourth of the lipid extract volume. After phase separation, the aqueous methanol phase is discarded. The initial chloroform-methanol proportion is restored by adding methanol to the organic lower phase, and a second wash is carried out using deionized water under the same conditions used in the first wash. The upper phase, containing non-lipid contaminants, is discarded and the chloroform lower phase is brought to dryness using a rotary evaporator. Traces of water are removed by sequentially adding absolute ethanol and drying the sample again, which is placed in a desiccator overnight. The mass of the total lipid is determined and the lipid is kept in a volume of benzene-methanol (1:1, v / v) at -30°C until further use.
[0184] 1.2. Saponification of total lipids. To remove ester lipids such as triglycerides, sterol-esters and glycerophospholipids, the lipids are subjected to mild alkaline methanolysis. In contrast, sphingolipids (including our molecules of interest) are resistant to saponification.
[0185] The latter is carried out in a mixture of chloroform-methanol (1:1, v / v) containing 0.3 M NaOH for 1 h at room temperature. The concentration of chloroform is then adjusted to obtain a chloroform-methanol ratio of (2:1, v / v). The non-saponifiable lipid fraction is then purified by phase partitioning after adding deionized water (one quarter of the chloroform-methanol volume). The aqueous upper phase is discarded and the chloroform lower phase is evaporated to dryness. The non-saponifiable lipid fraction is then dissolved in a volume of benzene-methanol (1:1, v / v).
[0186] 1.3. Deacylation of ceramide aminoethylphosphonate and purification of its lyso form. Deacylation was carried out using either strong alkaline or acid treatment: strong alkaline treatment was carried out with 1.5 M KOH in methanol at 100° C. for 24 h with stirring, and the reaction was stopped by the addition of concentrated HCl.
[0187] Acid hydrolysis was carried out using concentrated HCl-methanol (1:5, v / v) for 6 h at 75°C. After cooling, two liquid extractions were achieved using hexane. Strong alkaline hydrolysis allowed the formation of sphingosylaminoethylphosphonates (SAEPs), although some traces of unhydrolyzed CAEP are still detectable. To separate the precursors and reaction products, we developed a chromatographic procedure to purify the sphingosylaminoethylphosphonates. To do so, we used the fact that SAEPs display an additional amino group when compared to the CAEP precursor. Separation of the compounds was carried out using a weak cation exchange LC-WCX column. The column was first conditioned by successively applying hexane, 0.5 M acetic acid in methanol, methanol and then hexane. The sample was applied to the column in chloroform-methanol (9:2.5, v / v). Unhydrolyzed CAEP was eluted in the first fraction with chloroform-methanol (9:4, v / v) containing 0.1 M acetic acid. The SAEP was then eluted in the second fraction using methanol containing 1M acetic acid as the solvent system.
[0188] 1.4. Synthesis of SSL-X1, SSL-X2 and SSL-X3 by N-acylation. The SAEP produced and purified in the previous step (paragraph 1.3) was first quantified. This dosage was based on phosphorus determination, since each molecule of SAEP contains one carbon of phosphorus, thus allowing direct determination of the SAEP quantity. Dosage was realized spectrophotometrically after mineralization of the molecules in a mixture of concentrated sulfuric acid-concentrated perchloric acid (2:1, v / v) containing 1 g / L vanadium tetroxide as catalyst. Detection of inorganic phosphorus was performed after reaction with aminonaphthalenesulfonic acid.
[0189] Once quantified, SAEP was N-acylated with docosahexaenoic acid (DHA). N-acylation was carried out in a mixture of dichloromethane-dimethylformamide (3:1, v / v) containing diethyl phosphoryl cyanide as a coupling agent in the presence of triethylamine. The reaction was allowed to proceed in the dark in a nitrogen-saturated atmosphere at room temperature for 90 min with stirring. This procedure allowed the reaction without prior derivatization of the carboxylic acid functional group of DHA. The reaction conditions were established at the start of the reaction to proceed with a spontaneously "degraded" stoichiometry with a DHA / SAEP ratio lower than 2:1 (mol / mol). In this approach, the carboxylic acid group was introduced in limited quantities, allowing random N-acylation of one or two of the free amino groups of SAEP. This synthetic procedure allowed the simultaneous synthesis of SSL-X1, SSL-X2 and SSL-X3 in one pot at the same time. The different reaction products (SSL-X1, SSL-X2 and SSL-X3) were then separated and purified using an aminopropyl (LC-NH2) column preconditioned with hexane. Several fractions were eluted and collected from the column using the following solvent systems: F1 (not shown in FIG. 2): hexane-ethyl acetate (85:15, v / v); F2: diisopropyl ether-acetic acid (9:5, v / v); F3: acetone-methanol (9:1.35, v / v); F4: chloroform-methanol (2:1, v / v); F5: chloroform-methanol-3.6 M aqueous ammonium acetate (30:60:8, v / v / v). SAEP: control SAEP. The different fractions were evaporated under nitrogen, resuspended in a volume of chloroform-methanol (2:1, v / v) and applied to TLC. Lipids were separated using chloroform-methanol-ethanol-ethyl acetate-0.25% aqueous KCl (10:4:10:3.6, v / v / v / v / v) and revealed by charring. The results are illustrated in FIG. 2.
[0190] 2. Chemical synthesis Compounds SSL-X1, SSL-X2 and SSL-X3 are synthesized according to the following synthetic procedure: - The O-acetylation step makes it possible to neutralize the hydroxyl groups carried by the sphingoid base of the commercially available sphingomyelin, which serves here as a basic material for the synthesis of the molecule of interest. This O-acetylation is carried out at room temperature for 18 hours in the presence of pyridine and acetic anhydride. The N-acetylation phenomenon is prevented by the fact that the two amino groups of the sphingomyelin are substituted. - The second step is the hydrolysis of O-acetylated sphingomyelin by non-specific C-type phospholipase (Clostridium perfringens) to release O-acetylated ceramide, which is purified by simple phase partition in chloroform-methanol (1:1, v / v) and addition of deionized water. The purified O-acetylated ceramide is then phosphorylated after reaction with monochlorinated 2-phthalimidophosphonic acid, which makes it possible to synthesize O-acetyl-ceramide-(2-phthalimidoethyl)-phosphonate. - The next step is the hydrazinolysis of O-acetyl-ceramide-(2-phthalimidoethyl)-phosphonate, which allows the N-deacylation of O-acetyl-ceramide-(2-phthalimidoethyl)-phosphonate and the simultaneous release of the phthaloyl group. The O-acetylated sphingosylphosphoethanolamine thus produced is then purified by filtration, successive crystallization in 90% ethanol and then diisopropyl ether, followed by treatment on the strong cation exchanger Amberlite IR120H. The purified O-acetylated sphingosylphosphoethanolamine is then N-acylated (for example with docosahexaenoic acid) according to the procedure described in section 1.4 above. SSL-X1, SSL-X2 and SSL-X3 synthesized during this procedure are O-deacetylated by controlled alkaline methanolysis (0.6N NaOH in methanol, for 1 hour at room temperature) and then purified by phase partition and separation on an aminopropyl column.
[0191] I.2. Synthesis of SSL-Y compound (n=1) SSL-Y1, SSL-Y2 and SSL-Y3 were synthesized according to the same process, starting from commercially available ceramide phosphorylethanolamine (CPEA) as precursor. The synthesis was carried out according to the same procedure as for the synthesis of CEAP. For this, CPEA was deacylated as described in section 1.3 and sphingosylphosphorylethanolamine was N-acylated (with docosahexaenoic acid) as described in section 1.4.
[0192] I.3. Synthesis of AGPSL-X compounds (n=0) The procedure followed for the chemical synthesis of AGPSL-X is based on the same synthetic procedure used for the chemical synthesis of SSL-X, with the following differences:
[0193] Synthesis of AGPSL-X2: - The precursors used for the synthesis of AGPSL were 1,2-diacylglycerols of commercial origin esterified at the sn-1 position of glycerol, preferably with medium-chain saturated fatty acids (palmitic acid, stearic acid). The first synthesis step consisted of phosphorylating 1,2-diacylglycerol with monochlorinated phthalimidophosphonic acid. This phosphorylation reaction made it possible to obtain 1,2-diacylglycerol (2-phthalimidoethyl)phosphonate. - The second step consisted in the hydrazinolysis of the latter compound to obtain 1,2-diacylglycerol phosphonoethanolamine, which was dissolved in chloroform-methanol (2:1, v / v) and purified by phase partition after the addition of deionized water (one-quarter of the total volume of chloroform-methanol). - The third step consisted in deacylation of 1,2-diacylglycerol phosphonoethanolamine at the R2 position of glycerol using nonspecific phospholipase A2 (PLA2 from Apis millifera). The reaction was carried out with stirring at 37 °C for 40 min in diethyl ether-borate buffer (100 mM, pH 8.9) (1:1, v / v) containing 200 U phospholipase A2. At the end of the reaction, diethyl ether was evaporated under nitrogen and the samples were extracted with chloroform-methanol (2:1, v / v). Lipids were purified by phase partitioning by adding deionized water at a quarter volume of chloroform-methanol (2:1, v / v). - The 2-lyso, 1-acylglycerophosphonoethanolamines obtained during PLA2 hydrolysis were then purified in a fourth step by aminopropyl column solid-phase extraction, which made it possible to eliminate the fatty acids released under the action of PLA2. - The purified 2-lyso, 1-acylglycerophosphonoethanolamines were assayed (lipid phosphorus assay) and N-acylated, for example with docosahexaenoic acid, as described in section 1.4 for the synthesis of SSL-X2, thereby allowing the synthesis of AGPSL-X2.
[0194] Synthesis of AGPSL-X3: The synthesis of AGPSL-X3 was carried out by O-acylation of AGPSL-X2 in the presence of 1,3-dicyclohexylcarbodiimide and 4-(dimethylamino)pyridine, and then AGPSL-X3 was purified on an aminopropyl column.
[0195] Synthesis of AGPSL-X1: The synthesis of AGPSL-X1 was carried out starting from 1-acyl, 2-lysoglycerophosphonoethanolamine purified during step 4 of the synthesis of AGPSL-X2. 1-Acyl, 2-lysoglycerophosphonoethanolamine was O-acylated at R2 position with the fatty acid of interest (DHA, ...) in the presence of 1,3-dicyclohexylcarbodiimide and 4-(dimethylamino)pyridine) and then purified on an aminopropyl column.
[0196] I.4. Synthesis of AGPSL-Y compound (n=1) Synthesis of AGPSL-Y2: The synthesis of AGPSL-Y was carried out starting from phosphatidylethanolamine (cephalin) of commercial origin. This phosphatidylethanolamine was deacylated using nonspecific phospholipase A2 (Apis mellifera PLA2). The reaction was carried out under stirring conditions in diethyl ether-borate buffer (100 mM, pH 8.9) (1:1, v / v) containing 200 U phospholipase A2 for 40 min at 37 °C. At the end of the reaction, diethyl ether was evaporated under nitrogen and the sample was extracted with chloroform-methanol (2:1, v / v). The obtained 1-acyl-2-lysoglycerophosphorylethanolamine was purified by phase partitioning by adding deionized water in a ratio of one-fourth the volume of chloroform-methanol (2:1, v / v), followed by solid phase extraction on an LC-NH2 column. N-acylation with the target fatty acid (e.g., DHA) was carried out in a mixture of dichloromethane-dimethylformamide (3:1, v / v) containing diethylphosphoryl cyanide as a coupling agent in the presence of triethylamine. The reaction was carried out with stirring at room temperature for 90 min in the absence of light and under a saturated nitrogen atmosphere. AGPSL-Y2 was then purified by filtration, phase partitioning and aminopropyl column extraction.
[0197] Synthesis of AGPSL-Y3: The purified AGPSL-Y2 was then O-acylated at the R2″ position with the fatty acid of interest (DHA) and then purified by solid-phase extraction on an aminopropyl column.
[0198] Synthesis of AGPSL-Y1: AGPSL-Y1 was synthesized from commercially available phosphatidylethanolamine by O-deacylation using nonspecific phospholipase A2 (Apis mellifera PLA2) as described above for the synthesis of AGPSL-Y2. The obtained 1-acyl-2-lysoglycerophosphorylethanolamine was then purified by solid-phase extraction and then O-acylated at the R2" position with the desired fatty acid to obtain AGPSL-Y1, which was finally purified on an aminopropyl column.
[0199] I.5. Synthesis of metabolites resulting from intestinal hydrolysis of SSL and AGPSL The synthetic approach used is divided into two main steps: hydroxysuccinimidation and transamination. The following example describes the synthesis of synaptamide phosphonate starting from DHA as fatty acid. The protocol for the synthesis of any other N-acylethanolamine phosphonate is similar using the corresponding fatty acid.
[0200] The hydroxysuccinimidation step of DHA was carried out as follows: DHA (100 mg, 0.3 mmol) and N-hydroxysuccinimide (57.4 mg, 0.5 mmol) were diluted in 10 ml of ethyl acetate. α-Tocopherol (40 μM) was added to prevent potential oxidation of fatty acids. A solution of dicyclohexylcarbodiimide (DCC, 103 mg) in ethyl acetate (1 mL) was added to the previous solution. The reaction mixture saturated with nitrogen was left at room temperature, protected from light, under stirring, for at least 12 hours. To stop the reaction, DCC was filtered using an ashless filter and the filtrate was crystallized under nitrogen. To obtain better purification, the obtained material was dissolved in ethanol, filtered and recrystallized. The amount of N-hydroxysuccinimide DHA ester was determined by weighing: 126.3 mg. The transamination reaction was carried out as follows: N-hydroxysuccinimide DHA ester (50 mg) was diluted in tetrahydrofuran (10 mL). This solution was added to an aqueous mixture (10 mL) of phosphorylated ethanolamine (23.5 mg) or ethanolamine phosphonate (21 mg) and sodium bicarbonate (14 mg). The reaction was carried out at room temperature with stirring, protected from light, under a nitrogen-saturated atmosphere for at least 16 hours.
[0201] Each solution was transferred to a flask and then evaporated in a rotavapor. After evaporation, 50 mL of H2O was drawn into the flask and filtered through a filter paper into a new flask. Each flask was evaporated again. 40 mL of ethanol was drawn into the evaporated flask, filtered again, then 20 mL of ethanol was drawn into the flask and finally filtered once more. These latter flasks were evaporated in a rotavapor and weighed to quantify the phosphorylated and phosphonated synaptamide mass obtained. The flasks were drawn twice with 5 mL of ethanol and stored at -80°C. The molecules of interest produced (synaptamide, synaptamide phosphonate and phosphorylated synaptamide) were purified by reversed-phase liquid chromatography. The molecules thus synthesized were monitored by mass spectrometry (HR-ESI / MS). Synaptamide phosphonate: MS m / z[M+H+]=436.26; phosphorylated synaptamide: MS m / z[M+H+]=452.25
[0202] Example B biological results (Example B-1) Metabolic fate of SSL in the gastrointestinal tract Materials and Methods animal The rats used in our experiments were male Sprague-Dawley (Charles River, Saint Germain sur L'Arbresle, France) weighing approximately 200 g at the time of their receipt in an accredited animal facility maintained at a temperature of 21 °C under diurnal conditions (light period from 06:00 to 18:00). The rats were kept in groups of 5 individuals per cage and had free access to water and food. All animal testing procedures were in accordance with the European Directive 86 / 609, transposed into French law by Decree 87 / 848. Every effort was made to minimize animal suffering and stress as well as to reduce the number of animals used. The animals were used 2 weeks after their arrival at the animal facility.
[0203] Administration of SSL to animals A study on the fate of SSL in the digestive tract was carried out on SSL-X1. For this, an aliquot of SSL-X1 corresponding to 227 μg of lipid phosphonate was deposited in a glass tube. The solvent was evaporated under nitrogen. A second evaporation was performed after the addition of absolute ethanol. Then, 625 μl of an aqueous solution containing glucose (0.1 g glucose / mL) was added to the tube. The molecule was dissolved in the aqueous solution by gentle sonication (two 30 s sonications at 40 W power). The molecule was orally administered to the animals using a micropipette. Oral administration by gavage was not necessary and the animals spontaneously drank the solution presented to them.
[0204] To quantify the potential hydrolysis of SSL in rats in vivo, we performed two separate groups of experiments.
[0205] The inventors first orally administered the molecules to five rats as described in the previous paragraph. The animals were previously placed in individual cages. The purpose of this experiment was to quantify the molecules possibly present in rat feces. For this purpose, feces were collected at different times after the administration of the molecules. The feces collected at each time were pooled, and lipids were extracted and analyzed as described in the following paragraph.
[0206] In the second step, we administered the molecules to other rats. The rats were then sacrificed 5, 8, 24 and 36 hours after administration of the molecules. Sacrifice was achieved by lethal (250 mg / Kg) intraperitoneal injection of pentobarbital (Dolethal solution, Vetoquinol, Lure). Immediately after death, the peritoneal cavity was opened to remove the internal organs.
[0207] The entire intestine was removed from the pylorus region to the anus. The entire set was placed in a plastic trough to allow the tissue to stretch. The latter was then cut into approximately 10 cm pieces. The cecum was also collected separately. The large intestine was removed and divided into two equal parts. The contents of each intestinal segment were then removed by rinsing the intestinal lumen with an aqueous solution of NaCl 9‰. The contents of each intestinal segment were collected in a 125 ml flask for extraction and lipid analysis as described in the following paragraphs.
[0208] Fecal lipid analysis Extraction and purification of lipids from feces was performed as follows: - Trituration in 50 mL of chloroform-methanol (2:1, v / v) according to the method of Folch. Extraction of lipids for 24 hours at 4°C. - Filtration of the homogenate on an ashless filter. - A first washing of the crude lipid extract by adding an aqueous solution of KCl 0.25% (w / v) corresponding to 1 / 4 of the total volume of chloroform-methanol (2:1, v / v). - A second washing of the lipid extract by adding methanol corresponding to 1 / 3 of the initial total volume and deionized water corresponding to 1 / 4 of the total volume of chloroform-methanol (2:1, v / v). - Evaporation of the organic phase using a rotary evaporator. - Recovery of total lipids in two portions of 4 mL benzene-methanol (2:1, v / v). The lipid extract was then processed to isolate / purify the SSL-X1 molecules for quantification. Briefly, the lipid extract was saponified and washed. The saponified extract was then directly deposited on a 10x10 cm thin-layer chromatography plate. Taking into account the amount of lipids extracted by the sample, lipid deposition was performed on strips of 7 cm length. An aliquot of ceramide aminoethylphosphonate (corresponding to 10 micrograms of purified phospholipids) was also deposited in parallel on the same plate as the standard.
[0209] The deposited lipids were then separated in diisopropyl ether. This solvent was used to separate all neutral lipids from ceramide aminoethylphosphonate. In this system, this molecule remains deposited, whereas all of the neutral lipids (sterols, lipid products derived from saponification, bile salts) migrate to the solvent front. After separation, the chromatography plate was dried under a hot air stream and the plate was developed in chloroform-acetone-methanol-acetic acid-deionized water (50:20:10:15:5, v / v / v / v / v). After drying, the plate was revealed using Dittmer and Lester's reagent and the position of the SSL-X1 molecules was identified by standards that were deposited in parallel with the samples on the plate before transfer. The spot of SSL-X1 was then scraped off with a razor blade into a test tube, where the mineralization of the sample was carried out. The lipid phosphorus assay was then carried out.
[0210] result Quantification of hydrolysis – analysis of feces collected in cages To determine whether SSL-X1 molecule was efficiently hydrolyzed / absorbed in the rat digestive tract, we first administered a specific amount of the molecule (approximately 227 μg phosphorus / animal) to the animals. Then, all feces present in the cage were collected at different times (16, 21, 26, 40 and 50 hours) after administration. The amount of SSL-X1 measured in the feces at these different times is shown in Figure 3.
[0211] Analysis of feces collected in situ in the intestinal tract To determine the distribution of SSL-X1 in the intestinal tract of rats, animals were sacrificed at different times after administration of the molecule.Then, the entire intestinal tract was removed and the contents of the intestinal lumen were collected.The contents were collected on the sections (approximately 10 cm long) that the inventors realized throughout the tract.SSL-X1 was assayed for each of the lipid extracts made for the contents of each of the intestinal sections collected.
[0212] Figure 4 shows the results obtained in rats sacrificed 5 hours (Figure 4A), 8 hours (Figure 4B) and 36 hours (Figure 4C) after ingestion of the molecule. Ceramide aminoethyl phosphonate was detected / measured in all analyzed intestinal sections. These observations made it possible to make the following points regarding the physiology of lipolysis of SSL-X1: the molecule is able to reach the colon. These observations demonstrate that, when the molecule is hydrolyzed / absorbed in the digestive tract, a part of the ceramide aminoethyl phosphonate is able to reach the large intestine. This suggests that, although the two molecules differ in their structure due to the absence of a phosphate bond in SSL-X1, the intestinal hydrolysis of SSL-X1 follows a similar pathway as is known for sphingomyelin, another sphingophospholipid.
[0213] (Example B-2) Effects of SSLs and their metabolic derivatives on neuroinflammation B.2.1. Effect of metabolite derivatives of SSL and AGPSL on the inflammatory state of activated microglial cell lines of human origin. B.2.1.1. Cell culture Immortalized human microglia (IHM; Innoprot, Derio, Spain) were cultured at 13,000 cells / cm in T75 flasks coated with human collagen type I (10 μL / mL, coating matrix kit, Innoprot). 2 The medium was formulated for optimal growth of human brain-derived microglia in vitro and contained 1% penicillin / streptomycin, 1% microglia growth supplement, and 5% fetal bovine serum (Microglia Cell Medium Kit, Innoprot).
[0214] B.2.1.2. Time course of the inflammatory response IHM were seeded in 6-well plates coated with type 1 collagen (10,000 cells / cm 2). When cell cultures were approximately 80% confluent, IL-1β (R&D Systems) was added to the culture medium at 0.5 ng / mL, 1.5 ng / mL or 3.0 ng / mL. At t=0, each well received 1 mL of medium alone (control) or 1 mL of medium containing the desired concentration of IL-1β. Cells were harvested at t=0, t=3, t=8 and t=24 hours. Each test condition was repeated in triplicate.
[0215] B.2.1.3. Effects of synaptamide phosphonates on expression of inflammatory markers The effect of synaptamide phosphonates was tested as illustrated in Figure 5. IHM cells were cultured as mentioned in paragraph B.2.1.2 and when the cultures were about 80% confluent, they were incubated with one of the three following concentrations of synaptamide phosphonates (10, 150 or 300 nM) for 3 hours before adding IL-1β (3 ng / mL, t=0 hours). After 5 hours of incubation with IL-1β, the cells were then harvested for RNA extraction.
[0216] B.2.1.4. Measuring mRNA of interest using RT-qPCR 1. Total RNA extraction and purification Total RNA was extracted using Tri Reagent (MRC, Inc.) as recommended by the manufacturer, after which contaminating genomic DNA was removed from the samples by treatment with the Turbo DNA-free™ kit (Ambion).
[0217] 2. Calibrated reverse transcription (RT) of mRNA Messenger RNA (mRNA) contained in 480 ng of purified RNA extract was reverse transcribed using PrimeScript® RT Reagent (Ozyme). To normalize the RT step, a synthetic external and non-homologous poly(A) standard RNA (SmRNA; Morales and Bezin, patent WO2004.092414) was added to the RT reaction mix (150,000 copies in each experimental sample).
[0218] 3. qPCR Amplification of cDNA of Interest PCR amplification of target cDNA was performed using the Rotor-Gene Q system (Qiagen) and the Quantitect SYBR Green PCR kit (Qiagen). The sequences of the various primer pairs used for PCR amplification are listed in Table 1.
[0219] Taking into account that the same number of SmRNA copies was initially present in all samples before the RT step, the ScDNA copy number measured after qPCR was used to estimate the RT step yield for each sample. This yield made it possible to normalize the values obtained for all genes of interest measured from the same sample. This normalization method makes it possible to take into account variations in the efficiency of RT between samples, without having to resort to internal standards, so-called "housekeeping genes", whose expression is considered a priori invariant.
[0220] [Table 1]
[0221] B.2.2. Induction of neuroinflammation in vivo by lipopolysaccharide (LPS) injection First, we determined the time at which a maximum neuroinflammatory response could be observed in the pups after injection of LPS. For this purpose, 21-day-old Sprague-Dawley rats (Charles River, St Germain sur l'Arbresle, France) received an intraperitoneal injection of LPS (Sigma, ref. 055:B55) at a dose of 1 mg / Kg. This dose corresponds to the one usually used in the literature. The rats were then sacrificed 2, 4, 6, 10 and 24 hours after injection of LPS using a lethal dose of pentobarbital (250 mg / Kg, intraperitoneally) and perfused transcardially with an ice-cold solution of 0.9% NaCl. The hippocampus (HI) and neocortex were collected, frozen in liquid nitrogen and stored at -80 °C until analysis. Analysis of the expression levels of the main markers of neuroinflammation was performed by RT-qPCR as described above, using the primer pairs shown in Table 1. These preliminary experiments allowed us to determine that indeed, a peak in brain inflammation was observed 6 hours after injection of LPS. Rats that received any treatment to resolve LPS-induced neuroinflammation were then sacrificed 6 hours after LPS.
[0222] All studies aimed at studying the gene expression of different inflammatory markers analyzed each gene separately, making it difficult to construct conclusions regarding the evolution of the inflammatory state, especially when the expression of some genes increases while others remain stable or decrease. Since qPCR quantifies the number of cDNA copies in a given sample, we circumvented the difficulties mentioned above by developing for each sample a neuroinflammatory index (NI) that is the sum of all target cDNAs quantified by qPCR. However, in calculating this NI, we were careful not to mask large expression variations of genes expressed at low levels in basal conditions by small expression variations of genes expressed at high to very high levels in basal conditions. To this end, for each rat, the copy number of each cDNA was expressed as a percentage of the average copy number measured in the entire population of individuals considered. Once each cDNA was expressed as a percentage, the index was calculated by adding the percentages of each transcript involved in the composition of the index.
[0223] To test the effects of the hydrolysis products of SSL and AGPSL, we induced neuroinflammation by injection of LPS in rats as described above. One minute after LPS injection, the animals received an intraperitoneal injection of each of the various active ingredients carried by SSL and AGPSL.
[0224] The active compounds (synaptamide, synaptamide phosphonate) were administered at a dose of 2 mg / Kg equivalent of synaptamide. Taking into account the difference in molar mass between the two molecules, the dose of synaptamide phosphonate was adjusted to obtain a dose, expressed in nMole / Kg, equivalent to that of a dose of synaptamide administered at 2 mg / Kg. After 6 hours (optimal induction time of neuroinflammatory index, NI, see above), the animals were sacrificed, tissues were removed and transcript levels of key markers of neuroinflammation were determined by qPCR.
[0225] B.2.3. Effect of oral administration of SSL-X1 on status epilepticus-induced neuroinflammatory responses in rats Materials and Methods In these experiments, 21-day-old Sprague-Dawley rats (ENVIGO, The NETHERLAND) were subjected to pilocarpine-induced status epilepticus (SE) as described in detail below (§B.3). Three groups of rats were composed: (i) CTRL-NaCl, i.e. control rats that only received NaCl whenever treatment was given in the other groups of rats; (ii) SE-NaCl, i.e. rats subjected to SE and orally receiving NaCl instead of SSL-X1; (iii) SE-SSL-X1, i.e. rats subjected to SE and orally receiving SSL-X1 vector (100 mg / Kg) 1 hour after the onset of SE. The vectors were dissolved in 100 μL of NaCl. Due to their hydrophobic nature, the preparations were emulsified until complete dissolution of the lipid vectors. After 24 hours, the rats were sacrificed using a lethal injection of pentobarbital (250 mg / Kg; intraperitoneally) and brain tissues, i.e., hippocampus (HI) and ventral limbic region (including VLR, amygdala, piriform and agranular insular cortex), were collected and processed as mentioned above (§B.2.2). Analysis of the expression levels of key markers of neuroinflammation was performed by RT-qPCR as described above, using the primer pairs shown in Table 1. The time of sacrifice of the rats was chosen based on our preliminary experiments, which allowed us to determine that the peak of brain inflammation is observed 7 to 24 hours after the onset of SE.
[0226] result Effects of synaptamide phosphonates on inflammatory markers expressed by activated microglial cell lines The results show a dramatic reduction in IL-1β-mediated cytokine and chemokine gene induction in immortalized human microglia when cells were pretreated with 150 nM and 300 nM synaptamide phosphonate (FIG. 6).
[0227] Effects of synaptamide and synaptamide phosphonate, two metabolite derivatives of SSL and AGPSL, on the neuroinflammatory response induced in vivo by lipopolysaccharide (LPS) injection The results show that synaptamide and synaptamide phosphonate, when administered at a dose of 2 mg / Kg, partially prevent LPS-mediated induction of transcripts encoding neuroinflammatory markers. It is noteworthy that synaptamide and synaptamide phosphonate reduced the neuroinflammatory index measured in both the hippocampus and neocortex by ≈50% and ≈70%, respectively (Figure 7).
[0228] Effect of oral administration of SSL-X1 on the neuroinflammatory response to status epilepticus in rats. The results presented in Figure 8 show that transcripts encoding MCP1, IL6 and cyclooxygenase-2 (COX-2) are strongly increased in both the hippocampus and ventral limbic regions 24 hours after pilocarpine-induced status epilepticus (SE) in rats. Oral administration of SSL-X1 at a dose of 100 mg / Kg partially prevented this strong induction of key markers of the neuroinflammatory response to SE 1 hour after the onset of SE.
[0229] B.2.4. Effects of metabolite derivatives of SSL and AGPSL on the levels of IL-6 mRNA in activated macrophage cell lines of rat origin B.2.4.1. Cell culture, treatments and RT-qPCR NR8383 cells were cultured in T75 flasks at 53,000 cells / cm 2Cells were seeded at 100 ng / mL in medium consisting of Ham's F12K medium completed with 1% penicillin / streptomycin and 15% fetal bovine serum. Upon reaching confluence, they were treated with LPS (Sigma, ref. 055:B55) at a concentration of 100 ng / mL, followed by treatment for less than 2 min with one of the following conditions: DECA-EA-Pn at 10, 100, 500 or 1,000 nM, or EPA-EA-Pn at 10, 100, 500 or 1,000 ng / mL. Cells were harvested 5 h later, and the levels of IL-6 mRNA were measured by RT-qPCR as in B.2.1.4, using the primers listed in Table 1.
[0230] B.2.4.2. Results In a previous study, we determined that the apparent peak of IL6-mRNA levels in NR8383 cells appeared 5 hours after LPS treatment (100 ng / mL). Therefore, we tested the effect of DECA-EA-Pn and EPA-EA-Pn on IL-6 mRNA levels 5 hours after LPS treatment (Figure 21). The results show that the induction of IL-6 mRNA levels was significantly reduced by DECA-EA-Pn and EPA-EA-PN.
[0231] B.2.5. Effect of SYN and SYN-Pn on the resolution of inflammation after pilocarpine-induced status epilepticus (Pilo-SE) in rats B.2.5.1. Method Male Sprague-Dawley rats (Envigo, The Netherlands) were subjected to Pilo-SE at 42 days of age (185 g). SE was triggered by pilocarpine hydrochlorate (350 mg / kg, i.p.) 30 min after administration of scopolamine methylnitrate (1 mg / kg, subcutaneous), which was used to reduce peripheral side effects of pilocarpine. After 2 h of continuous SE, rats were administered diazepam (10 mg / kg, i.p.) to stop SE and then immediately treated with SYN (2 mg / kg, i.p.), SYN-Pn (2 mg / kg, i.p.) in 300 μL of NaCl. Naive rats subjected to Pilo-SE were injected with 300 μL of NaCl (i.p.) instead of SYN or SYN-Pn. All rats received a second dose of diazepam (5 mg / kg, subcutaneous) 1 h after the first dose and were sacrificed 9 h after SE. Brains were collected, hippocampi were microdissected on ice, RNA was extracted, and RT-qPCR was performed as described above using the primer pairs shown in Table 1. The time to sacrifice the rats was chosen based on our preliminary experiments, which allowed us to determine that peak brain inflammation was observed 7-12 h after the onset of SE.
[0232] B.2.5.2. Results Both SYN and SYN-Pn at 2 mg / kg reduced the induction of IL1β in response to Pilo-SE. SYN-Pn had a significant effect on TNFα-mRNA induction. As explained above, integrating the fluctuations of both IL1β and TNFα within the index, SYN-Pn had an improved effect in reducing the peak inflammatory response after Pilo-SE (Figure 22).
[0233] (Example B-3) Effects of SSL / AGPSL metabolic derivatives on cognition I.1. Materials and Methods animal In this experiment, we used male Sprague-Dawley rats (ENVIGO, Netherlands). Pups were received with their mothers at 14 days of age (postnatal day 14 (P14)) and were kept in plastic cages (405 mm x 255 mm x 197 mm) in groups of 10 with free access to food and water. All animal procedures followed the guidelines of the Animal Care and Use Committee of the Université Claude Bernard Lyon 1.
[0234] Pilocarpine-induced status epilepticus (Pilo-SE) All injection solutions were prepared in sterile saline (0.9% w / v). At weaning (postnatal day 20 (P20)), male Sprague-Dawley rat pups were initially injected intraperitoneally with lithium chloride (127 mg / Kg; Sigma-Aldrich) to reduce the dose of pilocarpine required to trigger status epilepticus (SE). Methylscopolamine nitrate (1 mg / Kg; Sigma-Aldrich) was injected subcutaneously 18 hours later to alleviate peripheral cholinergic adverse side effects. Pilocarpine hydrochloride (25 mg / Kg; Sigma-Aldrich) was injected intraperitoneally 30 minutes later to induce SE. After 30 min of continuous behavioral SE, diazepam (Valium®, Roche) was injected intraperitoneally at 10 mg / Kg to promote survival and initiate cessation of behavioral seizures, which was completely stopped after a second subcutaneous injection of diazepam given 90 min later at a dose of 5 mg / Kg. The rats were placed on a heating pad under continuous observation until they recovered from sedation. After recovery, the rats were returned to their nursing mothers until P23. Only control rats received saline injections. All rats were then housed in groups of 10 and weighed daily for the next 5 days and then twice a week until the end of the experiment (3 weeks after SE) to control food intake. Rats that had not gained weight on the second day after SE were sacrificed with a lethal dose of Doletal (250 mg / Kg; Vetoquinol, France).
[0235] Morris Water Maze (MWM) Test Spatial learning ability was measured by Morris Water Maze (MWM) 5 weeks after SE. The training apparatus was a circular white pool (120 cm diameter) containing 24°C water made opaque by the addition of black gouache. The platform (10 cm diameter) was submerged 1 cm below the water surface. The pool was divided into four virtual quadrants: North, East, South and West. The platform was hidden in the North quadrant. Four sessions were conducted (three trials per session per day). In the first trial, the rat was placed on the platform for 60 s. The rat was allowed to search for the platform for 90 s. If the rat did not find the platform within 90 s, it was gently guided towards it. All rats were allowed to remain on the platform for 15 s.
[0236] Electrophysiology Acute slice preparation and whole-cell recordings At P28–38, Sprague-Dawley rats were anesthetized with isoflurane, and the forebrains were removed and placed in ice-cold standard artificial cerebrospinal fluid (ACSF) consisting of (in mM): 124 NaCl, 5 KCl, 1.25 Na2HPO4, 2 MgSO4, 2 CaCl2, and 26 NaHCO3, supplemented with 10 D-glucose, and bubbled with 95% O2 and 5% CO2. Transverse hippocampal slices were cut into 350 μm-thick sections using a vibratome (Leica VT1000S) and incubated in ACSF for at least 1 h at room temperature before being transferred to the recording chamber. The ACSF used for perfusion was supplemented with picrotoxin (100 μM; Sigma-Aldrich) to block GABA-A receptors, thus facilitating the induction of NMDA receptor-dependent long-term potentiation (LTP). CA1 pyramidal cells were visualized with a Zeiss Axioscope 2 equipped with a 40x objective using infrared video microscopy and differential interference contrast optics. Whole-cell recordings from pyramidal neurons in the CA1 layer were acquired with patch electrodes filled with a solution containing (in mM): 120 potassium gluconate, 20 KCl, 0.2 EGTA, 2 MgCl2, 10 HEPES, 4 Na2ATP, 0.3 Tris-GTP, and 14 mM phosphocreatine (pH 7.3, adjusted with KOH). Drugs were applied in the bath of the hippocampal slice. Electrode resistance ranged from 3 to 5 MΩ. Series resistance was continuously monitored and the experiment was abandoned if it changed by more than 20%.
[0237] A capillary glass pipette filled with ACSF and connected to an Isoflex Stimulus Isolation Unit (AMPI) was placed in the stratum radiatum to evoke excitatory postsynaptic potentials (EPSPs) in CA1 pyramidal neurons. To record EPSPs, cells were held at -70 mV and the stimulation strength was set to evoke EPSPs between 5 and 8 mV. LTP was induced by a theta burst pairing (TBP) protocol, which consisted of an EPSP paired with a single backpropagating action potential (b-AP), timed such that the b-AP (with a delay of approximately 15 ms) occurred at the peak of the EPSP, as measured in the soma. A single burst containing 5 pairs was delivered at 100 Hz and 10 bursts were delivered at 5 Hz per sweep. Three sweeps were delivered with 10 s intervals for a total of 30 bursts (150 b-AP-EPSP pairs). b-APs were evoked by direct somatic current injection (1 ms, 1–2 nA). To avoid “washout” of LTP, this induction protocol was always applied within 20 min of achieving the whole-cell configuration.
[0238] Electrophysiological data acquisition and analysis EPSPs were recorded in whole-cell current clamp (Multiclamp 700B, Molecular Devices), filtered at 5 kHz, and digitized at 10 kHz (Digidata 1440A, Molecular Devices). Data were acquired and analyzed using pClamp 10 software (Molecular Devices). To generate LTP time course summary graphs, individual experiments were normalized to baseline and three consecutive responses were averaged to generate 1-min bins. Time courses per bin for all experiments within a group were then averaged to generate the final graph. LTP magnitude was calculated based on normalized EPSP amplitude 36–40 min after the end of the TBP protocol.
[0239] Drugs N-docosahexaenoylethanolamine (synaptamide, Cayman Chemical, France), synaptamide phosphonate, synaptamide phosphate, docosahexaenoic acid (DHA), eicosapentaenoic acid ethanolamine phosphonate (EPA-EA-Pn), decanoic acid ethanolamine phosphonate (DECA-EA-Pn) and SSLX2 are dissolved in saline (NaCl 0.9%). For in vivo experiments, drugs were administered intraperitoneally or orally 1 hour after the cessation of SE, then daily for 6 days, then once every other day for 2 weeks. Control groups received only saline. For ex vivo experiments, molecules were added in the perfusion bath.
[0240] statistical analysis Statistical analysis was performed using Sigma Plot software version 12. A paired Student's t-test was used to determine the significance of data in the same pathway. The Mann-Whitney U test was used to determine the significance between data groups. For the MWM test, data were analyzed by two-way repeated measures ANOVA followed by Fisher's LSD post-hoc test to compare differences between groups at several time points.
[0241] Results are expressed as mean±SEM. A value of p<0.05 was considered statistically significant.
[0242] I.2. Results Although a wide range of neuropsychological deficits can occur after status epilepticus (SE), cognitive impairment is the main common problem reported by people with epilepsy, and memory deficits are frequently reported in patients with temporal lobe epilepsy (TLE) and in animal models. LTP, a form of synaptic plasticity that is thought to reflect the processes of learning and memory formation in the hippocampus, is significantly disrupted in hippocampal neurons both in humans with epilepsy and in animal models of epilepsy, and thus impairment of LTP has been regarded as an important cellular mechanism underlying learning deficits in epilepsy. Therefore, we examined the effects of synaptamide, synaptamide phosphate, and synaptamide phosphonate on hippocampal LTP using a pilocarpine-induced experimental TLE model.
[0243] Synaptamide rescues hippocampal LTP deficits after pilocarpine-induced status epilepticus. Hippocampal LTP, an activity-dependent change in synaptic strength, has been proposed as a cellular mechanism underlying learning and memory. Our recent studies have revealed that hippocampal LTP is altered after pilocarpine-induced status epilepticus (Pilo-SE). In this study, we confirm these results in acute hippocampal slices prepared 1-2 weeks after pilocarpine-induced SE (Pilo-SE) by using whole-cell recordings from CA1 pyramidal neurons. Control neurons in slices prepared from control healthy animals exhibited robust LTP (Figure 9A; 162.3 ± 5.8% of baseline 36-40 min after induction, p < 0.001), whereas in slices prepared from rats subjected to Pilo-SE, LTP was significantly inhibited (Figure 9A; 109.6 ± 6.1%; t = 45-50 min; p = 0.13). The difference in LTP amplitude between the two groups of rats is highly significant (p<0.001).
[0244] We then investigated whether synaptamide perfusion could reverse Pilo-SE-induced LTP deficits. We showed that synaptamide bath application (100 nM) significantly enhanced LTP induction (Figure 9B; 166.8 ± 12.2%, t = 45-50 min, p < 0.001) compared to Pilo-SE slices perfused with ACSF alone (p < 0.001). Similarly, application of 400 nM synaptamide in the bath of slices prepared from rats subjected to Pilo-SE substantially increased LTP induction (164.2 ± 20.5%; t = 45-50 min; p = 0.014) compared to Pilo-SE slices perfused with ACSF alone (Figure 9C; p = 0.008). Interestingly, the LTP magnitude measured in Pilo-SE slices perfused with 100 nM or 400 nM synaptamide was similar to that in control healthy rats (FIGS. 9B-C, p>0.05).
[0245] We next examined the in vivo effects of synaptamide. Thus, we investigated whether daily synaptamide treatment (2 mg / Kg; i.p.) from day 0 (1 h post-SE) to day 7 post-SE could protect LTP induction in rats subjected to Pilo-SE. Control rats received saline instead of synaptamide. We found that rats injected with synaptamide exhibited a significant induction of LTP in hippocampal CA1 neurons (Figure 9D; 189.7 ± 11.4%, t = 45-50 min; p < 0.001) compared to their saline-injected counterparts (p < 0.001). These findings reveal that the impairment of hippocampal LTP during epileptogenesis can be rescued or prevented by synaptamide treatment.
[0246] We next investigated whether intraperitoneal administration of 5 and 10 mg / Kg synaptamide could protect LTP induction in rats subjected to Pilo-SE.Similarly, we demonstrated that LTP induction was significantly enhanced (151.54±7.15%, t=45-50 min; p<0.001) in slices prepared from rats subjected to Pilo-SE and injected with 5 mg / kg synaptamide compared to rats subjected to Pilo-SE and injected with saline (Figure 9E; p<0.01). In addition, we found that treatment of rats subjected to Pilo-SE with 10 mg / kg synaptamide substantially increased LTP induction (195.2 ± 8%; t = 45–50 min; p < 0.001) compared to saline-injected Pilo-SE rats (Figure 9E; p < 0.001).
[0247] Synaptamide phosphate rescues hippocampal LTP deficits after pilocarpine-induced status epilepticus. We synthesized a synaptamide-related compound, synaptamide phosphate, which is more water-soluble than synaptamide. To date, synaptamide phosphate has not been characterized and its biological activity has not been investigated. Therefore, we tested the in vitro and in vivo effects of synaptamide phosphate on hippocampal synaptic plasticity when given after Pilo-SE, using a protocol similar to that used above for synaptamide. We found that, like synaptamide, application of synaptamide phosphate (100 nM) in the bath of slices prepared from rats subjected to Pilo-SE significantly enhanced LTP induction (144.5 ± 9.39%; t = 45-50 min; p = 0.002) compared to Pilo-SE slices perfused with ACSF only (Figure 10A, p = 0.007). Similarly, LTP induction was also reversed in slices prepared from animals subjected to Pilo-SE and perfused with 400 nM synaptamide phosphate (150.4 ± 15.4%, t = 45–50 min; p = 0.01) when compared with Pilo-SE slices perfused with ACSF alone ( Fig. 10<em>B , P = 0.046).
[0248] We next evaluated the LTP magnitude in slices prepared from rats subjected to Pilo-SE and injected with synaptamide phosphate (5 mg / Kg; i.p.). We found that LTP induction was significantly enhanced in these animals (162.3 ± 10.8%, t = 45-50 min; p < 0.001) compared to rats subjected to Pilo-SE and injected with saline (Figure 10C, p < 0.001). In contrast, there was no significant difference in the amplitude of LTP monitored in slices obtained from synaptamide phosphate-treated rats and those of healthy control animals (p = 0.494), pointing to the ability of synaptamide phosphate as a synaptamide to restore and reverse LTP after Pilo-SE.
[0249] We next evaluated LTP magnitude in slices prepared from rats subjected to Pilo-SE and injected (i.p.) with 2 mg / kg synaptamide phosphate. We found that synaptamide phosphate treatment at 2 mg / kg significantly enhanced LTP induction (Figure 10D, 168.9 ± 7.1%; t = 45-50 min; P < 0.001) compared to saline-injected Pilo-SE rats (p < 0.001). These findings reveal that impairment of hippocampal LTP during epileptogenesis can be rescued or prevented by synaptamide phosphate treatment.
[0250] Synaptamide phosphonates rescue hippocampal LTP deficits after pilocarpine-induced status epilepticus. We also synthesized a non-hydrolyzable synaptamide derivative, synaptamide phosphonate. Like synaptamide phosphate, synaptamide phosphonate has not been characterized and its biological activity has never been investigated. Therefore, we explored the in vitro and in vivo effects of synaptamide phosphonate on hippocampal LTP induction in rats subjected to Pilo-SE. We found that LTP was blocked in slices prepared from rats subjected to Pilo-SE, but neurons in the same slices perfused with synaptamide phosphonate (100 nM) exhibited robust LTP (Figure 11A, 132.2 ± 5.01%; t = 36-40 min; p < 0.001). LTP magnitude was significantly higher (159.9 ± 10.7%, t = 45-50 min; P < 0.001) when slices prepared from rats subjected to Pilo-SE were perfused with 400 nM synaptamide phosphonate (Figure S1B).
[0251] In addition, we found that synaptamide phosphonate treatment (5 mg / Kg; i.p.) significantly enhanced LTP induction (Figure 11C, 162.4 ± 11.9%; t = 45-50 min; P < 0.001) compared to saline-injected Pilo-SE rats (p < 0.001). The LTP magnitude measured in Pilo-SE rats was similar to that of control healthy rats (p = 0.726). Thus, our data reveal that the impairment of hippocampal LTP during epileptogenesis can be prevented and rescued by synaptamide phosphonate treatment.
[0252] We next explored the magnitude of LTP in slices prepared from rats subjected to Pilo-SE and injected (i.p.) with 2 or 10 mg / kg synaptamide phosphonate. We demonstrate that rats injected with 2 mg / kg synaptamide phosphonate exhibited a significant induction of LTP in hippocampal CA1 neurons (Figure 11D; 183.07 ± 9.02%, t = 45-50 min; p < 0.001) compared to their saline-injected counterparts (p < 0.001). In addition, we found that LTP induction was significantly enhanced in slices prepared from rats subjected to Pilo-SE and injected with 10 mg / kg synaptamide phosphonate (162.78 ± 12.23%, t = 45-50 min; p < 0.001) compared to rats injected with saline (Figure S1D, p < 0.001).
[0253] We finally investigated whether oral administration of 10, 30 and 100 mg / kg synaptamide phosphonate could also protect LTP induction in rats subjected to Pilo-SE. We show that LTP induction remained abnormal in slices prepared from rats subjected to SE and treated with 10 mg / kg synaptamide phosphonate (Figure 11E, 110.7 ± 4.7%; t = 45-50 min; p = 0.041). Indeed, the LTP amplitude of this group is highly different from that recorded in hippocampal slices of healthy rats (p < 0.001), but similar to that of rats subjected to Pilo-SE and receiving saline (p = 0.79). However, we found that treatment with 30 mg / kg synaptamide phosphonate significantly enhanced LTP induction (Figure 11E, 146.16 ± 10%; t = 45-50 min; P < 0.001) compared to Pilo-SE rats receiving saline (p = 0.007). We also found that rats receiving 100 mg / kg synaptamide phosphonate exhibited significant induction of LTP in hippocampal CA1 neurons (Figure 11E; 162.6 ± 9.2%, t = 45-50 min; p < 0.001) compared to their saline-injected counterparts (p < 0.001). These findings reveal for the first time that oral administration of synaptamide phosphonate dose-dependently prevents hippocampal LTP dysfunction after SE.
[0254] Overall, this is the first demonstration of a protective role for synaptamide, synaptamide phosphonates and synaptamide phosphate against epilepsy-associated cognitive deficits (LTP dysfunction).
[0255] Synaptamide and synaptamide phosphonates improve hippocampal LTP induction in healthy rats. Our next goal was to examine whether synaptamide or synaptamide phosphonate treatment could improve hippocampal LTP induction in healthy rats. Therefore, we first explored the magnitude of LTP in slices prepared from healthy rats injected with synaptamide. We found that rats injected with synaptamide (2 mg / Kg; i.p.) exhibited a significant induction of LTP in hippocampal CA1 neurons (Figure 12A; 211.9 ± 15.14%; t = 45-50 min; p < 0.001) compared to their saline-injected counterparts (p < 0.01). In addition, we showed that synaptamide phosphonate treatment substantially increased LTP induction in healthy rats (212.11 ± 12.9%; t = 45-50 min; p < 0.001) compared to saline-injected counterparts ( p < 0.001).
[0256] Overall, this is also the first demonstration of a beneficial role for synaptamides and synaptamide phosphonates in improving cognitive function in healthy subjects by modulating hippocampal LTP.
[0257] Synaptamide and synaptamide phosphonate treatment prevents learning deficit impairment in epileptic rats. In these experiments, we examined whether protection of LTP induction by synaptamide and synaptamide phosphonate treatment at early stages after SE also protects spatial learning after the onset of epilepsy (5 weeks after SE). As indicated in Figure 15, all four groups demonstrated improvement in water maze performance during the four days of testing, with a decrease in latency to platform from day 1 to day 4. Control healthy rats performed substantially better than epileptic rats (Figure 15A, p<0.001). Treatment with synaptamide during the first week after SE significantly increased spatial learning acquisition in rats that developed epilepsy after SE (Figure 15B, p<0.01). This effect was characterized by increased latency to find the platform on trial days 2 and 4 in synaptamide-treated rats compared to saline-injected epileptic animals. In addition, treatment with synaptamide phosphonates increased the mean latency to find the platform compared to saline injections, which was observed only on trials 2 and 4 (FIG. 15C, p<0.05). Thus, these data demonstrated that treatment with synaptamide or synaptamide phosphonates at an early stage after SE prevents learning deficits after the onset of epilepsy.
[0258] Synaptamide phosphonates facilitate recovery of weight loss in rats after status epilepticus. Rats were subjected to pilocarpine-induced status epilepticus on day 0 and synaptamide phosphonate (SynPn) was administered daily (10 mg / Kg, intraperitoneally) for 7 days. Animals were weighed daily. Results are depicted in Figure 20. Results are expressed as percentage of animal body weight on day 0 (10-15 animals / group). Statistical differences between control / SE+NaCl (*: p<0.05, ***: p<0.001) and SE+NaCl / SE+SynPn (#: p<0.05).
[0259] Oral administration of docosahexaenoic acid does not prevent impairment of hippocampal LTP after status epilepticus. Synaptamide is an endogenous metabolite of DHA. However, synaptamide phosphonate is a non-hydrolyzable synaptamide derivative. In this experiment, we investigated whether oral administration of docosahexaenoic acid (DHA) at a dose equivalent to 100 mg / kg synaptamide phosphonate could protect LTP induction in rats subjected to Pilo-SE, as synaptamide phosphonate does. We found that rats subjected to DHA exhibited a slight induction of LTP in hippocampal CA1 neurons (Figure 16; 129.5 ± 10.2%, t = 45-50 min; p = 0.011). However, the enhancement of EPSP amplitude in slices from these animals was not statistically significant compared to those of rats subjected to Pilo-SE and receiving saline (p = 0.214). These findings demonstrated that, unlike synaptamide phosphonates, oral administration of 100 mg / kg DHA was unable to rescue hippocampal LTP deficits following Pilo-SE. These data also revealed that synaptamide phosphonates were more effective than DHA in enhancing LTP induction in rats subjected to SE.
[0260] Altogether, these data suggest that synaptamide and related compounds offer new possibilities for the treatment of cognitive dysfunction associated with neurological and / or neurodegenerative diseases, particularly epilepsy.
[0261] Oral administration of SSLX2 prevents dysfunction of hippocampal LTP after status epilepticus To determine the benefit of carrying synaptamide phosphonate delivered by SSLX2 lipid vectors, the effect of oral administration of synaptamide phosphonate on LTP was compared to SSLX2 delivering the same amount of active ingredient. We previously demonstrated that oral administration of synaptamide phosphonate dose-dependently prevents hippocampal LTP dysfunction after SE. We next investigated whether oral administration of SSLX2 (administered at doses equivalent to 10 and 30 mg / kg synaptamide phosphonate) could also protect LTP induction in rats subjected to Pilo-SE. We demonstrated that rats receiving 10 mg / kg SSLX2 exhibited a slight induction of LTP in hippocampal CA1 neurons (Figure 17A-B; 135.6 ± 9.9%, t = 45-50 min; p = 0.003). However, the enhancement of EPSP amplitude in slices from these animals was not statistically different from that of rats subjected to Pilo-SE and receiving saline (p=0.07) or from that recorded in hippocampal slices from healthy animals (p=0.07). Moreover, this amount of LTP was larger than, but not statistically different from, that induced in slices from rats injected with the same dose (10 mg / kg) of synaptamide phosphonate (Figure 17B; P=0.128). Notably, when slices were prepared from rats subjected to Pilo-SE receiving 30 mg / kg SSLX2, the LTP magnitude was significantly higher (172.9±6.5%, t=45-50 min; P<0.001) (Figures 17A and 17C). Indeed, this magnitude of LTP was statistically significant compared to that recorded in slices from Pilo-SE rats receiving either saline solution (Fig. S4C; P < 0.001) or an equivalent dose of synaptamide phosphonate (Fig. S4C; P = 0.46). These findings demonstrated that, like synaptamide phosphonate, oral administration of SSLX2 dose-dependently prevents hippocampal LTP dysfunction after SE.These data also revealed that when synaptamide phosphonates are delivered in the SSLX2 form, their effect on LTP induction in rats subjected to SE is enhanced (a spectacular effect) compared to synaptamide phosphonates alone.
[0262] Both eicosapentaenoic acid ethanolamine phosphonate and decanoic acid ethanolamine phosphonate prevent hippocampal LTP dysfunction after SE The SSLX2 vector can deliver synaptamide phosphonates containing DHA. It can also deliver other potential synaptamide phosphonate-like active ingredients according to the identification of the fatty acid attached at the R3 position. Therefore, we tested the potential effect of synaptamide phosphonate-like compounds containing short / medium chain fatty acid chains (decanoic acid (C10)) or other long chain PUFAs (eicosapentaenoic acid (C20:5 w3)) instead of DHA (present in synaptamide phosphonates) on hippocampal LTP induction. Towards these goals, we synthesized decanoic acid ethanolamine phosphonates (DECA-EA-Pn) and EPA ethanolamine phosphonates (EPA-EA-Pn) according to the protocol disclosed in section I.5 of Example A. So far, these molecules have not been characterized and their biological activity has not been investigated. We therefore examined the in vivo (i.p.) effects of both DECA-EA-Pn and EPA-EA-Pn on hippocampal LTP when given after Pilo-SE, using a protocol similar to that used above for the synaptamide phosphonates. We found that LTP induction was enhanced (130.3 ± 7%, t = 45-50 min; p < 0.001) in slices prepared from rats injected with DECA-EA-Pn (5 mg / kg) compared to rats subjected to Pilo-SE and injected with saline (Figure 18, p = 0.038). Moreover, we also demonstrated that LTP induction was significantly enhanced (154.4±12.1%, t=45-50 min; p<0.001) in slices prepared from rats subjected to Pilo-SE and injected with 5 mg / kg EPA-EA-Pn, compared to rats subjected to Pilo-SE and injected with saline (FIG. 18, p=0.006). Overall, these findings revealed that treatment with decanoic acid ethanolamine phosphonate or EPA ethanolamine phosphonate, which, like synaptamide phosphonate, can be delivered by SSLX2 vectors, can also prevent the impairment of hippocampal LTP in rats subjected to Pilo-SE.
[0263] (Example B-4) Effect of synaptamide phosphonate (SYN-PN) on epileptic seizures The kindling model is a model of chronic epilepsy currently used by antiseizure drug (ASD) discovery programs (Loscher et al., 2011, Seizure 20, 359-368).
[0264] 1. Materials and Methods All animal procedures complied with the European Union guidelines regulating animal experiments (Directive 2010-63) and were approved by the Ethics Committee of the Université Claude Bernard Lyon 1. Male Sprague-Dawley rats (Envigo, France) were used in these experiments. They were housed in a temperature-controlled room (23 ± 1 °C) under diurnal lighting conditions (lights on from 6 am to 6 pm). The rats arrived 15 days before the start of the experiment. The rats were kept in groups of two in 800 cm2 plastic cages with minimal environmental enrichment (cardboard nesting boxes, wooden gnowing bars) and were given free access to food and water.
[0265] For surgical implantation of kindling electrodes, rats weighing 220-240 g were anesthetized using isoflurane (5% induction; 2% maintenance) and treated with the analgesic buprenorphine (0.050 mg / kg, intramuscularly). Their heads were positioned in a stereotaxic apparatus with the incisor bar set at -3.3 mm. Burr holes were drilled in the left parietal, right frontal, and occipital bones over the sites of implantation of the electrodes used for amygdaloid kindling for placement of three stainless steel jewelers' screws. The stimulating and recording electrodes consisted of Teflon-insulated bipolar stainless steel electrodes aimed at the right basolateral amygdala (stereotaxic coordinates relative to bregma: anterior-posterior, -2.8 mm; lateral, +4.8 mm; dorso-ventral, -8.5 mm). The screws placed over the parietal and frontal cortices served as recording electrodes, and the screw placed over the cerebellum served as ground. Bipolar recording and ground electrodes were connected to plugs that were fixed to the skull with dental acrylic cement.
[0266] Electrical stimulation via kindling electrodes was started after a one week recovery period after surgery and was performed at the same time of the day (between 9:00 and 11:00 am, then between 4:00 and 6:00 pm) to avoid diurnal variation between animals. Constant current stimulation (500 μA, biphasic square wave pulse, 50 pulses / sec for 2 sec) was delivered twice a day until at least five fully kindled seizures (secondarily generalized stage 5 seizures) were induced. Seizure severity was classified behaviorally according to the Racine scale: stage 1, immobility, slight facial clonus (eye closure, vibrissa twitching, sniffing); stage 2, head nodding with more severe facial clonus; stage 3, clonus of one forelimb; stage 4, rearing often with bilateral forelimb clonus; stage 5, tonic-clonic seizures with loss of balance and falling.
[0267] To evaluate the effect of SYN-PN on seizure severity, SYN-PN was prepared in saline and injected intraperitoneally at 5, 10 or 50 mg / kg 45 min prior to electrical stimulation in fully kindled rats. Briefly, on day 1, the day following the final stage 5 seizure, rats received the first dose of SYN-PN (5 mg / kg) and were stimulated 45 min later. On D2 and D5, rats were stimulated without SYN-PN injection to evaluate the residual effect of the 5 mg / kg dose. On D6, rats received a second dose of SYN-PN (10 mg / kg) and were stimulated 45 min later. Rats were then stimulated on D7 and D8 to evaluate the residual effect of the 10 mg / kg dose. On D9, rats received a third dose of SYN-PN (50 mg / kg) and were stimulated 45 min later. Rats were then stimulated on D10 and D11 to evaluate the residual effect of the 50 mg / kg dose. Finally, rats received 1) a daily dose of 5 mg / kg SYN-PN from D12 to D15 and stimulated on D16, 2) a daily dose of 10 mg / kg SYN-PN from D19 to D22 and stimulated on D23, and 3) a daily dose of 20 mg / kg SYN-PN from D26 to D29 and stimulated on D30. Treatment was then stopped. However, to assess the durability of the effect of this series of treatments, rats continued to be stimulated 7, 15, 42 and 56 days after the last treatment with 20 mg / kg.
[0268] 2. Results The day before D0, all included rats (n=15) developed at least five consecutive stage 5 seizures. Looking at the total population of rats (FIG. 13A), rats developed stage 4 (n=1) or stage 5 (n=14) seizures on D0.
[0269] On D1, all rats received 5 mg / kg SYN-PN 45 min before stimulation, and the mean seizure severity was reduced by 19.0 ± 7.9%. Interestingly, the mean reduction in seizure severity was maintained at -23.1 ± 8.1% on D2 and then reached significance (p = 0.019). This transient effect was lost on D5. The next day, on D6, rats received a higher dose of SYN-PN (10 mg / kg), and the severity of seizures triggered 45 min later was not significantly different from that on D0. However, a delayed effect was also observed with this dose, and on the next and following days the reduction became significant (p < 0.001) compared to D0, reaching a maximum of -39.4 ± 11.1%. Increasing the SYN-PN dose to 50 mg / kg on D9 reinforced the decrease in seizure severity on D10, reaching -54.4 ± 9.4% compared to D0 (p<0.001), but not significant compared to D8. Finally, while maintaining the lowest daily dose of SYN-PN tested (5 mg / kg), stimulation was stopped from D12 to D14, followed by D16, which kept seizure severity at its lowest level (-42.0 ± 9.2% compared to D0; p<0.001).
[0270] Individual examination of the effects of SYN-PN administration was demonstrated for three groups of rats: those that responded to 5 mg / kg (8 / 15; FIG. 13B), 10 mg / kg (3 / 15; FIG. 13C), or 50 mg / kg (4 / 15; FIG. 13D).
[0271] For rats responding to the 5 mg / kg dose (FIG. 13B), a reduction in seizure severity was observed on the day of dosing (−36.4±11.7% compared to D0; p<0.001), while the greatest reduction was observed 2 days after the 10 mg / kg dose (−62.3±12.7% compared to D0; p<0.001). Surprisingly, cessation of stimulation from D12 to D14, while maintaining a daily dose of SYN-PN of 5 mg / kg, followed by an even greater reduction in seizure severity on D16 (−87.0±13.0% compared to D0; p<0.001), with 7 / 8 rats remaining in stage 0 and 1 / 8 rats reverting to stage 5.
[0272] For rats responding to the 10 mg / kg dose (FIG. 13C), the intensity of the reduction was more variable, resulting in observed effects that were not significantly different from D0. However, the severity reduction was maintained even on D16 after the SYN-PN dose was reduced to 5 mg / kg for 4 days.
[0273] For rats that responded to the 50 mg / kg dose (FIG. 13D), the magnitude of reduction was also too variable to observe a significant effect compared to D0. However, seizure reduction was only transient and was lost on D16 after the SYN-PN dose was reduced to 5 mg / kg over 4 days.
[0274] In all cases, the maximal effect on seizure severity was observed to be delayed 24 to 48 hours after administration of any dose of SYN-PN. When this maximal effect was compared in the three groups of rats after each of the doses tested, the reduction in severity produced by the lowest dose was not amplified by the higher doses (Figure 14).
[0275] After examining the effect of a daily dose of 5 mg / kg over 4 consecutive days (D12 to D15) (Figure 13), we examined the effect of a dose of 10 mg / kg and then 20 mg / kg using the same administration protocol. Finally, when treatment was stopped, we examined whether the protective effect on seizure absence or seizure severity was maintained, and if so, whether it was a persistent long-lasting effect. Figure 19 shows the effect observed at the final dose of 50 mg / kg (black bars), then after 4 daily doses of 5 mg / kg, 4 daily doses of 10 mg / kg, and 4 daily doses of 20 mg / kg (hatched bars), and finally the seizure severity after treatment was stopped for 7, 15, 42, and 56 days (dotted bars) for each of the three groups of rats. The number of rats that were seizure-free in the indicated sessions is also listed directly below the x-axis.
[0276] For the group of rats that responded to the 5 mg / kg dose from the first dose, increasing the daily dose from 5 to 10 and then to 20 mg / kg did not change the mean severity of seizures.
[0277] However, it was interesting to note that a greater number of rats were seizure-free at the 5 mg / kg dose (7 / 8) compared to the 10 mg / kg dose (4 / 8). This more modest effect at 10 mg / kg can possibly be explained by the fact that when the 5 mg / kg daily dose was tested, 4 / 8 rats were still under the protective effect of the 50 mg / kg dose. In fact, it was noted that at the higher dose (20 mg / kg), in the group of rats that responded to 50 mg / kg, the protective effect against seizures could persist for up to 15 days after treatment was stopped (Figure 19).
[0278] This significant absence of seizures was observed in a subset of rats from the three groups of animals, but an even more striking result was the absence of seizures in a significant proportion of rats (7 / 15 rats) 15 days after treatment was stopped.
[0279] Thus, SYN-PN appears to be a disease-modifying drug in a significant proportion of rats, relieving them of seizures even after treatment had ceased for nearly 2 months.
Claims
1. Compound of formula (IIA): R 5 -NH-CH 2 -CH(R 7 )-PO 3 2- (IIA) [In the formula, ○ R 5 represents a saturated or unsaturated fatty acyls containing from 2 to 30 carbon atoms selected from the group consisting of propionic acid, butyric acid, valeric acid, caprylic acid, capric acid, lauric acid, myristic acid, stearic acid, arachidic acid, behenic acid, lignoceric acid, myristoleic acid, palmitoleic acid, oleic acid, vaccenic acid, linoleic acid, alpha-linoleic acid, arachidonic acid, eicosapentaenoic acid, erucic acid and docosahexaenoic acid, or one of the oxygen derivatives thereof, ○ R 7 is hydrogen or (C 1 ~C 6 ) alkyl group, and A hydrate, or a diastereoisomer, or a pharmacologically acceptable salt thereof.
2. ○ R 5 represents a saturated or unsaturated fatty acyl group containing from 2 to 30 carbon atoms, which is docosahexaenoic acid; ○ R 7 represents hydrogen, 2. The compound of claim 1.
3. R 5 but, - a saturated or unsaturated fatty acylate containing from 2 to 30 carbon atoms, selected from the group consisting of capric acid, eicosapentaenoic acid and docosahexaenoic acid, or - oxygen derivatives of saturated or unsaturated fatty acyls containing from 2 to 30 carbon atoms selected from resolvins, maresins, neuroprotectins and neuroprostanes; 2. The compound according to claim 1, which represents:
4. 4. A compound according to any one of claims 1 to 3 for use as a medicine.
5. 4. A pharmaceutical composition comprising at least one compound according to any one of claims 1 to 3 and an acceptable pharmaceutical excipient.
6. 6. The pharmaceutical composition according to claim 5, for use in preventing and / or treating a disease selected from among inflammatory diseases or diseases associated with cognitive impairment.
7. 7. The pharmaceutical composition according to claim 6, wherein the inflammatory disease is an inflammatory disease of the central nervous system, an inflammatory disease of the gastrointestinal tract, an inflammatory joint disease, or an inflammatory disease of the retina.
8. 6. The pharmaceutical composition of claim 5 for use in preventing and / or treating a disease selected from the group consisting of epilepsy, traumatic brain injury, Alzheimer's disease, Parkinson's disease, multiple sclerosis, Crohn's disease, bowel syndrome, dementia and Huntington's disease.
9. 6. The pharmaceutical composition of claim 5 for use in preventing cognitive decline or in restoring cognitive function altered in brain injury and / or in traumatic brain injury and / or in neuroinflammatory diseases and / or in neurodegenerative diseases.
10. 10. The pharmaceutical composition according to any one of claims 6 to 9, wherein the pharmaceutical composition is administered by oral route.
Citation Information
Patent Citations
Production of stereoisomer of 1-amino-alkyl sulfonic acid or1-amino-alkyl phosphinic acid
JP1986088895A
N-acyl-aminomethylphosphonate and preparation thereof
JP1990262585A
Method of calibration of reverse transcription using a synthetic messenger RNA (SMRNA) as an internal control
WO2004092414A1
N-acylethanolamide derivatives and uses thereof
WO2018071679A1
Acefapc for the treatment of acetylcholine-dependent diseases
WO2018162617A1
